2025 年起有新融资的美欧 biotech 总表:262 家
更新:2026-11-05。本表是本板块的入口:每家公司一行,字段覆盖地点、模态、融资、投资人、状态、wet-lab 模式、中国提供方、是否 NewCo、是否 AI 公司、官方 X 账号。详细分类分析和 70 家逐家证据见本板块下一篇。
配套页面:Startup X map — US/EU biotech 2025–26。它基于同一份公司清单核对了每家的官方 X(Twitter)账号:74 / 263 家有可信的公司账号(28%),美国 57/202、欧洲 17/61;按匹配置信度高 47、中 22、低 5。有 X 账号的公司里自建 39%、混合 35%、虚拟 14%,远高于全样本的虚拟比例,因为 NewCo 和隐身期公司大多不开官方账号。粉丝数最高的是 Isomorphic Labs(66k)、NewLimit(43k)、Life Biosciences(24k)、Chai Discovery(7.1k)、Lila Sciences(4.5k)。本表最后两列即来自该页。
口径
- 样本:2025-01 起有新融资的美国和欧洲 biotech,来源为 BioPharma Dive 融资追踪(26 家头部 VC 的组合,任意金额,截至 2026-10-30)加 Fierce Biotech Fundraising Tracker($50M 以上,截至 2026-09-30)。两源按日期 ±14 天和金额去重。
- 缺口:$50M 以下且非 26 家 VC 投的轮次基本缺失,欧洲小轮缺得最多;2026 年 10 月只有 BioPharma Dive 部分。
- wet-lab 模式:自建 = 发现阶段湿实验主要在自有实验室;混合 = 自有实验室加明确命名的外包环节;虚拟 = 发现阶段没有自有实验室(外包给 CRO、授权方或学术实验室)。括号内 H/M/L 为置信度。
- NewCo:围绕授权引进或收购资产建立、没有自有发现管线的公司。AI 公司:公开描述以 AI / 计算驱动为核心。
- 中国提供方:是 = 有命名的中国 CRO/CDMO 或授权方;? = 未找到信息。
- X 账号:只收公司官方账号,不收创始人账号;粉丝数为 2026-11 初快照。
汇总
| 家数 | 自建 | 混合 | 虚拟 | 不明 | NewCo | AI 公司 | 中国提供方=是 | 有 X 账号 | |
|---|---|---|---|---|---|---|---|---|---|
| 全部 | 262 | 89 | 66 | 105 | 2 | 51 | 48 | 48 | 74 |
| 美国 | 201 | 70 | 51 | 78 | 2 | 41 | 38 | 39 | 57 |
| 欧洲 | 61 | 19 | 15 | 27 | 0 | 10 | 10 | 9 | 17 |
| 融资时阶段 | 家数 | 自建 | 混合 | 虚拟 | 有 X 账号 |
|---|---|---|---|---|---|
| Preclinical | 90 | 44 | 19 | 25 | 19 |
| Phase 1 | 69 | 21 | 19 | 29 | 16 |
| — | 53 | 17 | 16 | 20 | 16 |
| Phase 2 | 37 | 4 | 8 | 25 | 15 |
| Phase 3 | 8 | 3 | 1 | 4 | 5 |
| Marketed | 2 | 0 | 0 | 2 | 2 |
| Undisclosed | 2 | 0 | 2 | 0 | 1 |
| Phase 0 | 1 | 0 | 1 | 0 | 0 |
| 模态 | 家数 | 自建 | 混合 | 虚拟 | 有 X 账号 |
|---|---|---|---|---|---|
| Small molecules | 73 | 19 | 9 | 44 | 14 |
| Biologics | 70 | 26 | 16 | 27 | 17 |
| — | 53 | 17 | 16 | 20 | 16 |
| Cell or gene therapy | 32 | 17 | 11 | 4 | 13 |
| Nucleic acids | 11 | 4 | 4 | 3 | 4 |
| Multiple | 6 | 0 | 3 | 3 | 4 |
| Undisclosed | 5 | 3 | 1 | 1 | 0 |
| Drug discovery | 4 | 1 | 2 | 1 | 3 |
总表(美国在前,按累计披露金额降序)
| # | 公司 | 地区 | 国家 / 城市 | 模态 | 疾病领域 | 融资时阶段 | 轮次 | 最新一轮 | 累计 $M | 投资人(点开看全部) | 状态 | wet-lab | 中国提供方 | NewCo | AI | X 账号 | 粉丝 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chai Discovery | 美国 | USA / San Francisco CA | Drug discovery | Undisclosed | Undisclosed | 3 轮2025-08-06 Series A $70M2025-12-15 Series B $130M 2026-07-14 Series C $400M |
2026-07-14 Series C $400M | 600 | Menlo VenturesMenlo Ventures, with new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC and others, and existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, Fred Ehrsam and others / Oak HC/FT, General Catalyst, Thrive Capital, OpenAI, Dimension, Menlo Ventures, Lachy Groom, Yosemite, Neo, SV Angel, Emerson Collective and Glade Brook / Index Ventures / Bain Capital Life Sciences |
私有 | 混合(M) | ? | ✓ | @chaidiscovery | 7.1k | |
| 2 | Kailera Therapeutics | 美国 | USA / Waltham, MA | Multiple | Metabolic diseases | Phase 2 | 1 轮 | 2025-10-14 Series B $600M | 600 | Bain Capital Private EquityBain Capital Life Sciences / Bain Capital Life Sciences, Atlas Venture / Bain Capital Private Equity, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, Qatar Investment Authority, Royalty Pharma, Citadel's Surveyor Capital, accounts advised by T. Rowe Price Associates, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Si |
上市 | 虚拟(H) | 是 | ✓ | @kaileratx | 117 | |
| 3 | NewLimit | 美国 | US / South San Francisco | Cell or gene therapy | Other | Preclinical | 2 轮2025-05-06 Series B $130M2026-06-02 Series C $435M |
2026-06-02 Series C $435M | 565 | Founders FundKleiner Perkins, Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, Valor Equity Partners, Dimension, Founders Fund and Brian Armstrong / Founders Fund, Thrive Capital, Greenoaks, Quiet Capital / Eli Lilly and Company / Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital and ot |
私有 | 自建(H) | ? | ✓ | @newlimit | 43k | |
| 4 | Kardigan | 美国 | USA / South San Francisco, CA | Undisclosed | Other | Undisclosed | 2 轮2025-01-10 Series A $300M2025-10-14 Series B $254M |
2025-10-14 Series B $254M | 554 | Fidelity Management & Research CompanyPerceptive Advisors, Arch Venture Partners, Sequoia Heritage / Arch Venture Partners / Perceptive Advisors, ARCH Venture Partners and Sequoia Heritage / Fidelity Management & Research Company, accounts advised by T. Rowe Price Investment Management, ARCH Venture Partners and Sequoia Heritage |
上市 | 混合(M) | ? | — | — | ||
| 5 | Lila Sciences | 美国 | US / Cambridge MA | — | — | — | 3 轮2025-03-10 Seed $200M2025-09-15 Series A $235M 2025-10-14 A extension $115M |
2025-10-14 A extension $115M | 550 | Flagship PioneeringFlagship Pioneering, General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures and a wholly owned subsidiary of the Abu Dhabi Investment Authority / Braidwell, Collective Global, Altitude Life Science Ventures, Alumni Ventures, ARK Venture Fund, Common Metal, Flagship Pioneering, General Catalyst, Ma |
私有 | 自建(H) | 否 | ✓ | @LilaSciences | 4.5k | |
| 6 | Ollin Biosciences | 美国 | US / South San Francisco | Biologics | Eye diseases | Phase 1 | 2 轮2025-09-17 Series A $100M2026-06-24 Series B $330M |
2026-06-24 Series B $330M | 430 | TCGXArch Venture Partners, Mubadala Capital, Monograph Capital / Arch Venture Partners / ARCH Venture Partners, Mubadala Capital and Monograph Capital / TCGX, ARCH Venture Partners, a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a leading so |
私有 | 虚拟(H) | 是 | ✓ | @OllinBio | 30 | |
| 7 | Beeline Medicines | 美国 | USA / Boston, MA | Multiple | Immune diseases | Phase 2 | 2 轮2026-04-15 Series A $300M2026-06-30 Series A $126M |
2026-06-30 Series A $126M | 426 | Bain Capital Life SciencesBain Capital / Bain Capital Life Sciences / Bain Capital and others |
私有 | 虚拟(H) | ? | ✓ | @BeelineMed | 0 | |
| 8 | Dispatch Bio | 美国 | USA / Philadelphia, PA | Cell or gene therapy | Cancer | Preclinical | 1 轮 | 2025-07-23 Series A $201M | 417 | Arch Venture PartnersArch Venture Partners, Parker Institute for Cancer Immunotherapy / Arch Venture Partners, Alexandria Venture Investments / Arch Venture Partners, Parker Institute for Cancer Immunotherapy, Bristol Myers Squibb, the University of Pennsylvania, Stanford University and Alexandria Venture Investments |
私有 | 混合(H) | 否 | @DispatchBio | 81 | ||
| 9 | MapLight Therapeutics | 美国 | US / Redwood City | Small molecules | CNS disorders | Phase 2 | 1 轮 | 2025-07-28 Series D $373M | 373 | Forbion and Life Sciences at Goldman SacForbion, Goldman Sachs Alternatives / Forbion, Novo Holdings / Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors Sanofi, accounts advised by T. Rowe Price Investment Management and Avego BioScience Capital, and existing investors including funds managed by Novo Holdings, 5AM Ventures, Blue Owl Healthcare Opportunities and others |
上市 | 混合(H) | ? | @Maplightrx | 242 | ||
| 10 | Eikon Therapeutics | 美国 | USA / Millbrae, CA | Multiple | Multiple | Phase 3 | 1 轮 | 2025-02-26 Series D $351M | 351 | Lux CapitalAlexandria Venture Investments / Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, E15 VC, Foresite Capital, General Catalyst, Soros Capital, StepStone Group, funds and accounts advised by T. Rowe Price Associates, and UC Investments (Office of the Chief Investment Officer of the Regents of the University of California), among others |
上市 | 混合(H) | ? | @EikonTX | 954 | ||
| 11 | Dren Bio | 美国 | USA / San Mateo, CA | Biologics | Cancer | Phase 3 | 1 轮 | 2026-10-29 Series C $350M | 350 | Juvia GroupJuvia Group, Lightspeed Venture Partners / OrbiMed |
私有 | 自建(M) | ? | @DrenBio | 5 | ||
| 12 | Abcuro | 美国 | USA / Newton MA | Biologics | Multiple | Phase 3 | 2 轮2025-02-12 Series C $200M2026-08-18 Series D $77M |
2026-08-18 Series D $77M | 343 | New Enterprise AssociatesNEA / NEA, RA Capital Management, Bain Capital Life Sciences, Samsara BioCapital, Sanofi Ventures / New Enterprise Associates, Foresite Capital, RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventures, Pontifax, Mass General Brigham Ventures, New Leaf Ventures, funds managed by abrdn, funds and accounts managed by BlackRock, Eurofarma Ventures and Soleus |
私有 | 虚拟(M) | 否 | @abcuro | 16 | ||
| 13 | Soufflé Therapeutics | 美国 | US / Watertown MA | Nucleic acids | Rare diseases | Preclinical | 2 轮2025-10-07 Series A $200M2026-10-13 Series B $135M |
2026-10-13 Series B $135M | 335 | Polaris PartnersPolaris Partners, Arch Venture Partners, Novo Holdings / Juvia Group / Arch Venture Partners, Polaris Partners |
私有 | 自建(M) | ? | — | — | ||
| 14 | Crystalys Therapeutics | 美国 | USA / San Diego, CA | Small molecules | Immune diseases | Marketed | 2 轮2025-09-30 Series A $205M2026-07-22 Series C $130M |
2026-07-22 Series C $130M | 335 | Frazier Life SciencesNovo Holdings, SR One, Catalys Pacific / Alexandria Venture Investments, Novo Holdings / Novo Holdings, Catalys Pacific, SR One, Lightstone VC, Longwood Fund, Alexandria Venture Investments and others / Frazier Life Sciences / Novo Holdings, Alexandria Venture Investments / Frazier Life Sciences, Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge |
私有 | 虚拟(M) | ? | ✓ | @Crystalys_Tx | 11 | |
| 15 | Expedition Medicines | 美国 | USA / San Francisco Bay Area, CA | Small molecules | Other | Phase 2 | 3 轮2025-10-09 Series A $165M2025-10-22 未披露轮 $50M 2026-08-05 Series B $115M |
2026-08-05 Series B $115M | 330 | Sofinnova InvestmentsSofinnova Investments, Novo Holdings / Forbion, Sofinnova Investments, Sanofi Ventures, Novo Holdings / Sofinnova Investments, Novo Holdings, Forbion, KKR's Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, BVF Partners and Venrock Healthcare Capital Partners / Flagship Pioneering / General Atlantic / RA Capital Management, Vivo Capital, Novo Holdings, Forbion, Sofinnova Investments, Sa |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 16 | Star Therapeutics | 美国 | US / South San Francisco | Biologics | Rare diseases | Phase 3 | 2 轮2025-09-30 Series D $125M2026-10-23 未披露轮 $200M |
2026-10-23 未披露轮 $200M | 325 | Sanofi VenturesSanofi Ventures, Viking Global Investors / OrbiMed, Sofinnova Investments, RA Capital Management, Sanofi Ventures / Sanofi Ventures, Viking Global Investors, Sofinnova, Blue Owl Capital, RA Capital Management, Janus Henderson Investors, Fraizer Life Sciences, GordonMD Global Investments and others / OrbiMed, Janus Henderson Investors / OrbiMed, RA Capital Management, Sofinnova Investments |
私有 | 自建(M) | ? | @STAR_Biotech | 41 | ||
| 17 | Korsana Biosciences | 美国 | USA / Boston, MA | Biologics | CNS disorders | Preclinical | 2 轮2025-09-01 Series A $150M2026-02-18 Seed / A $175M |
2026-02-18 Seed / A $175M | 325 | FairmountWellington Management, TCGX / Sanofi Ventures / Fairmount, Venrock Healthcare Capital Partners, Wellington Management, TCGX, J.P. Morgan Life Sciences Private Capital, Janus Henderson Investors, Sanofi Ventures, Foresite Capital and others |
反向并购 | 虚拟(H) | 是 | ✓ | — | — | |
| 18 | Kriya Therapeutics | 美国 | USA / Redwood City, CA | — | — | — | 1 轮 | 2025-08-18 Series N/A $313M | 313 | N/A | 私有 | 自建(H) | 否 | @kriyatx | 280 | ||
| 19 | Enveda | 美国 | USA / Boulder, CO | — | — | — | 1 轮 | 2026-09-23 Series E $311M | 311 | Catalio Capital ManagementCatalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), Digitalis Ventures, a notable Sovereign Wealth Fund, and Alderline Group, Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital |
私有 | 自建(H) | ? | ✓ | @enveda | 2.7k | |
| 20 | Parabilis Medicines | 美国 | US / Boston | Biologics | Cancer | Phase 1 | 1 轮 | 2026-01-08 Series F $305M | 305 | RA Capital ManagementRA Capital Management, Fidelity Management & Research, Janus Henderson Investors / RA Capital Management, venBio, Arch Venture Partners, GV / RA Capital Management, Fidelity Management & Research Company, Janus Henderson Investors, Frazier Life Sciences, Soleus Capital, a life science-dedicated investment fund, venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky |
上市 | 混合(H) | 是 | ✓ | @FogPharma | 43 | |
| 21 | Encoded Therapeutics | 美国 | USA / South San Francisco, CA | Cell or gene therapy | CNS disorders | Phase 1 | 1 轮 | 2026-09-09 Series F $275M | 275 | Google VenturesGV / GV, Arch Venture Partners, / Google Ventures, another healthcare fund, ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2 and Venrock |
私有 | 自建(H) | ? | @EncodedTx | 320 | ||
| 22 | Atrium Therapeutics | 美国 | USA / San Diego | — | — | — | 1 轮 | 2026-02-27 Series N/A $270M | 270 | N/A | 上市 | 混合(M) | ? | — | — | ||
| 23 | Mirador Therapeutics | 美国 | US / San Diego | Drug discovery | Immune diseases | Preclinical | 1 轮 | 2026-01-12 Series B $250M | 250 | Arch Venture Partners, OrbiMed | 私有 | 混合(M) | ? | — | — | ||
| 24 | Serapha Bio | 美国 | US / San Diego | — | — | — | 1 轮 | 2026-06-23 Series A $230M | 230 | RA Capital ManagementRA Capital Management, RTW Investments, Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, LifeSci Venture Partners, Logos Capital, Balyasny Asset Management and Eventide Asset Management |
反向并购 | 虚拟(M) | 是 | ✓ | — | — | |
| 25 | Solstice Oncology | 美国 | US / Boston | Biologics | Cancer | Phase 1 | 1 轮 | 2026-09-09 Series A $225M | 225 | RA Capital ManagementRA Capital Management / RA Capital Management, Forbion / RA Capital Management, Canaan Partners, Forbion and others |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 26 | Odyssey Therapeutics | 美国 | US / Boston | Small molecules | Immune diseases | Phase 2 | 1 轮 | 2025-09-10 Series D $213M | 213 | Affinity Asset AdvisorsOrbiMed, Alexandria Venture Investments / Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, Wedbush Healthcare Partners and all existing investors |
上市 | 混合(H) | 是 | ✓ | @odysseytx | 19 | |
| 27 | Aviceda Therapeutics | 美国 | USA / Cambridge MA | Small molecules | Other | Phase 2 | 1 轮 | 2025-01-07 Series C $208M | 208 | Omega Funds and TCGXOmega Funds, TCGX / OrbiMed / Co-led by Omega Funds and TCGX, with participation from Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital, Marshall Wace, Catalio Capital Management, funds managed by abrdn Inc., and Digitalis Ventures |
私有 | 混合(M) | ? | ✓ | — | — | |
| 28 | AirNexis Therapeutics | 美国 | USA / Palo Alto CA | Small molecules | Other | Phase 2 | 1 轮 | 2026-01-09 Series A $200M | 200 | Frazier Life SciencesFrazier Life Sciences / OrbiMed / Frazier Life Sciences, OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences, among others |
私有 | 虚拟(M) | 是 | ✓ | @AirNexis | 0 | |
| 29 | Treeline Biosciences | 美国 | US / Massachusetts | Multiple | Cancer | Phase 1 | 1 轮 | 2025-09-03 Series A $200M | 200 | Arch Venture Partners, OrbiMed, GV / N/A | 反向并购 | 混合(M) | ? | @TreelineBio | 32 | ||
| 30 | Tenvie Therapeutics | 美国 | US / South San Francisco | Small molecules | CNS disorders | Preclinical | 1 轮 | 2025-01-08 未披露轮 $200M | 200 | Arch Venture PartnersArch Venture Partners, F-Prime Capital, Mubadala Capital / Arch Venture Partners, F-Prime Capital / Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors |
私有 | 虚拟(M) | 是 | ✓ | ✓ | — | — |
| 31 | Soley Therapeutics | 美国 | US / South San Francisco | — | — | — | 1 轮 | 2026-01-07 Series C $200M | 200 | Surveyor CapitalSurveyor Capital, HRTG Partners, RWN Management, Doug Leone Family Fund, Breyer Capital and GordonMD Global Investments |
私有 | 自建(M) | ? | ✓ | — | — | |
| 32 | Osanni Bio | 美国 | US / San Francisco | — | — | — | 1 轮 | 2026-06-23 Series B $190M | 190 | Patient Square CapitalPatient Square Capital, Horowitz Group, Invus Opportunities and the Retinal Degeneration Fund |
私有 | 混合(M) | ? | — | — | ||
| 33 | LifeMine Therapeutics | 美国 | US / Cambridge MA | Small molecules | Other | Phase 1 | 1 轮 | 2026-08-06 Series E $188M | 188 | Milky Way InvestmentsMilky Way Investments / RA Capital Management, GV, Arch Venture Partners / Milky Way Investments, Bezos Expeditions, Gates Frontier, RA Capital Management, Google Ventures, LoLa Capital Partners, GSK, Invus and ARCH Venture Partners |
私有 | 自建(H) | ? | ✓ | — | — | |
| 34 | Callio Therapeutics | 美国 | USA / Seattle WA | Biologics | Cancer | Preclinical | 1 轮 | 2025-03-03 Series A $187M | 187 | Frazier Life SciencesFrazier Life Sciences / Novo Holdings / Frazier Life Sciences, Jeito Capital, Novo Holdings, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 35 | Braveheart Bio | 美国 | USA / San Francisco CA | Small molecules | Other | Phase 3 | 1 轮 | 2025-11-05 Series A $185M | 185 | Andreessen Horowitz (a16z Bio + Health)Forbion, OrbiMed / Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital) and Frazier Life Sciences |
上市 | 虚拟(H) | 是 | ✓ | — | — | |
| 36 | Electra Therapeutics | 美国 | USA / South San Francisco, CA | Biologics | Multiple | Phase 2 | 1 轮 | 2025-10-22 Series C $183M | 183 | NextechEQT Life Sciences, Nextech Invest / EQT Life Sciences, OrbiMed, RA Capital Management, Sanofi Ventures / Nextech, EQT Life Sciences, Sanofi, HBM Healthcare Investments, Mubadala Capital, OrbiMed, Redmile Group, New Leaf Venture Partners, Westlake BioPartners, Cormorant Asset Management, Blue Owl Capital and RA Capital Management |
上市 | 混合(H) | 是 | @ELECTRA_Biotech | 31 | ||
| 37 | Celea Therapeutics | 美国 | USA / Boston MA | Small molecules | Other | Phase 2 | 1 轮 | 2026-07-02 未披露轮 $180M | 180 | RA Capital ManagementRA Capital Management / RA Capital Management, Leaps by Bayer, PureTech Health, a “large, U.S.-based healthcare-focused fund” and a “leading sovereign wealth fund” |
私有 | 虚拟(M) | ? | — | — | ||
| 38 | cAMPfield Therapeutics | 美国 | USA / San Diego | Small molecules | Immune diseases | Phase 2 | 1 轮 | 2026-06-18 Series A $180M | 180 | ForbionFrazier Life Sciences / Forbion, Novo Holdings, RA Capital Management |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 39 | Timberlyne Therapeutics | 美国 | US / | Biologics | Immune diseases | Phase 1 | 1 轮 | 2025-01-09 Series A $180M | 180 | AbingworthAbingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners / Bain Capital Life Sciences / Led by Abingworth, Bain Capital Life Sciences and Venrock Healthcare Capital Partners, with Boyu Capital, Lilly Asia Ventures, Braidwell LP and 3H Health Investment |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 40 | Antares Therapeutics | 美国 | USA / Boston MA | Small molecules | Cancer | Preclinical | 1 轮 | 2025-06-10 Series A $177M | 177 | Omega FundsAtlas Venture, Omega Funds, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management / Atlas Venture / Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, Cormorant Asset Management, Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures and Willett Advisors |
私有 | 自建(H) | ? | — | — | ||
| 41 | Tune Therapeutics | 美国 | US / Salt Lake City | Cell or gene therapy | Infectious diseases | Phase 1 | 2 轮2025-01-12 Series B $175M2025-01-13 Series B $175M |
2025-01-13 Series B $175M | 175 | New Enterprise AssociatesNEA, Yosemite, Regeneron Ventures, Hevolution Foundation / NEA / Led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation |
私有 | 自建(M) | ? | @tunetx_news | 1.1k | ||
| 42 | Syremis Therapeutics | 美国 | US / Boston | Multiple | CNS disorders | Phase 1 | 1 轮 | 2025-12-18 Series A $165M | 165 | Dexcel PharmaDexcel Pharma, Third Rock Ventures / Bain Capital Life Sciences, GV, Third Rock Ventures / Dexcel Pharma, Third Rock Ventures, Bain Capital Life Sciences, GV (Google Ventures), QVT and Pictet |
私有 | 虚拟(L) | ? | ✓ | — | — | |
| 43 | Atavistik Bio | 美国 | USA / Cambridge MA | Small molecules | Other | Phase 1 | 2 轮2025-12-18 Series B $120M2026-03-05 Series B $40M |
2026-03-05 Series B $40M | 160 | Nextech InvestNextech Invest, The Column Group, Lux Capital and Regeneron Ventures / RA Capital Management |
私有 | 自建(M) | ? | — | — | ||
| 44 | Altesa BioSciences | 美国 | USA / Wayne PA | Small molecules | Other | Phase 2 | 1 轮 | 2026-02-19 Series B $85M | 160 | ForbionForbion / Forbion, Sanofi, Medicxi, Pitango and Atlantic Partners |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 45 | Alveus Therapeutics | 美国 | USA / Philadelphia | — | — | — | 1 轮 | 2026-01-08 Series A $160M | 160 | Andera PartnersAndera Partners, New Rhein Healthcare Investors, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital and others |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 46 | Epicrispr Biotechnologies | 美国 | USA / South San Francisco, CA | Cell or gene therapy | Rare diseases | Phase 1 | 2 轮2025-03-26 Series B $68M2026-08-11 Series C $90M |
2026-08-11 Series C $90M | 158 | Octagon CapitalAlly Bridge Group, SOLVE FSHD and other investors / Octagon Capital, Janus Henderson Investors / Sanofi Ventures / Octagon Capital, Janus Henderson Investors, Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital and existing investors |
私有 | 混合(H) | 否 | @EpicrisprBio | 308 | ||
| 47 | AIRNA | 美国 | USA / Cambridge MA | Cell or gene therapy | Rare diseases | Preclinical | 1 轮 | 2025-04-01 Series B $155M | 155 | Venrock Healthcare Capital PartnersVenrock Healthcare Capital Partners, Forbion / Arch Venture Partners / Venrock Healthcare Capital Partners, Forbion Growth, RTW Investments, Nextech Invest, ARCH Venture Partners, Forbion Ventures, ND Capital and other unnamed investors |
私有 | 自建(M) | ? | @AirnaBio | 0 | ||
| 48 | Strand Therapeutics | 美国 | US / Boston | Nucleic acids | Cancer | Phase 1 | 1 轮 | 2025-08-07 Series B $153M | 153 | KinnevikKinnevik / Eli Lilly and Company / Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, Gradiant Corporation, FPV Ventures, Playground Global, Eli Lilly, ANRI and Potentum |
私有 | 混合(M) | ? | @StrandTx | 2.3k | ||
| 49 | Arthrosi Therapeutics | 美国 | USA / Palo Alto CA | — | — | — | 1 轮 | 2025-10-08 Series E $153M | 153 | Prime Eight Capital LimitedPrime Eight Capital Limited, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited and existing shareholders |
被收购 | 虚拟(M) | 是 | ✓ | — | — | |
| 50 | Matchpoint Therapeutics | 美国 | US / Cambridge MA | Small molecules | Immune diseases | Preclinical | 1 轮 | 2026-10-07 Series B $150M | 150 | Sanofi VenturesNextech Invest, Norwest / Sanofi Ventures, Atlas Venture |
私有 | 自建(M) | ? | @matchpointtx | 138 | ||
| 51 | Atsena Therapeutics | 美国 | USA / Durham NC | Cell or gene therapy | Other | Phase 1 | 1 轮 | 2025-04-02 Series C $150M | 150 | Bain CapitalBain Capital Life Sciences / Bain Capital Life Sciences, Sofinnova Investments / Bain Capital, Sofinnova Investments, Abingworth, Wellington Management, Lightstone Ventures, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners and the Manning Family Foundation |
私有 | 混合(H) | 否 | — | — | ||
| 52 | Latigo Biotherapeutics | 美国 | USA / Thousand Oaks, CA | — | — | — | 1 轮 | 2025-03-17 Series B $150M | 150 | Blue Owl CapitalBlue Owl Capital, Deep Track Capital, Access Biotechnology, Qatar Investment Authority and Sanofi Ventures |
上市 | 混合(H) | 是 | @latigobio | 2 | ||
| 53 | Infinimmune | 美国 | USA / Alameda, CA | Biologics | Immune diseases | Preclinical | 1 轮 | 2026-08-11 Series A $65M | 140 | Regeneron VenturesRegeneron Ventures, Playground Global / RA Capital Management / Regeneron Ventures, Playground Global, RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital, Wild Tree Ventures, Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC |
私有 | 混合(H) | 否 | @infinimmune | 139 | ||
| 54 | Grin Therapeutics | 美国 | USA / New York, NY | — | — | — | 1 轮 | 2025-05-27 Series D $140M | 140 | Angelini Pharma and Blackstone Life ScieAngelini Pharma and Blackstone Life Sciences |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 55 | Sidewinder Therapeutics | 美国 | USA / San Diego, CA | Biologics | Cancer | Preclinical | 1 轮 | 2026-04-08 Series B $137M | 137 | Frazier Life SciencesFrazier Life Sciences, Novartis Venture Fund / OrbiMed, Samsara BioCapital, Alexandria Venture Investments / Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund and Astellas Venture Management |
私有 | 混合(L) | ? | — | — | ||
| 56 | Slate Medicines | 美国 | US / Raleigh | Biologics | CNS disorders | Preclinical | 1 轮 | 2026-02-24 Series A $130M | 130 | RA Capital ManagementRA Capital Management, Forbion, Foresite Capital / RA Capital Management, Forbion / RA Capital Management, Forbion, Foresite Capital and an unnamed biotech investor |
反向并购 | 虚拟(H) | 是 | ✓ | — | — | |
| 57 | Angitia Biopharmaceuticals | 美国 | USA / Westlake Village CA | Biologics | Other | Phase 2 | 1 轮 | 2026-02-05 Series D $130M | 130 | Frazier Life SciencesFrazier Life Sciences, Venrock Healthcare Capital Partners / RA Capital Management, Bain Capital Life Sciences, OrbiMed / Frazier Life Sciences, Venrock Healthcare Capital Partners, Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management, Wellington Management. Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Healt |
私有 | 自建(M) | 是 | — | — | ||
| 58 | Corsera Health | 美国 | USA / Boston, MA | Nucleic acids | Other | Phase 1 | 2 轮2025-09-02 Series N/A $50M2026-01-07 Series A $80M |
2026-01-07 Series A $80M | 130 | Clive MeanwellClive Meanwell, John Maraganore and other undisclosed individuals / Forbion, Population Health Partners / Forbion / Forbion, Population Health Partners and others |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 59 | Protego Biopharma | 美国 | USA / San Diego, CA | Small molecules | Rare diseases | Phase 1 | 1 轮 | 2025-12-01 Series B $130M | 130 | Novartis Venture FundForbion, Novartis Venture Fund / Forbion / Novartis Venture Fund, Forbion, Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures, Vida Ventures, MPM BioImpact, Lightspeed Venture Partners and Scripps Research |
私有 | 自建(M) | ? | — | — | ||
| 60 | Stylus Medicine | 美国 | US / Watertown MA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2025-05-13 Series A $45M | 130 | RA Capital ManagementRA Capital, Eli Lilly and Company / RA Capital Management, Khosla Ventures, Chugai Venture Fund, Eli Lilly, Johnson & Johnson Innovation, the Myeloma Investment Fund and Tachyon Ventures |
私有 | 自建(M) | ? | — | — | ||
| 61 | SonoThera | 美国 | US / South San Francisco | Cell or gene therapy | Rare diseases | Preclinical | 1 轮 | 2026-06-10 Series B $125M | 125 | Vida VenturesVida Ventures / Vivo Capital, Arch Venture Partners, Alexandria Venture Investments, RA Capital Management / Vida Ventures, ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation, Medical Excellence Capital, RA Cap |
私有 | 自建(H) | ? | — | — | ||
| 62 | Ray Therapeutics | 美国 | US / Berkeley, CA | Cell or gene therapy | Other | Phase 1 | 1 轮 | 2026-04-21 Series B $125M | 125 | Janus Henderson InvestorsDeerfield Management, Novo Holdings / Janus Henderson Investors, with participation from new investors Adage Capital Management, Franklin Templeton, Invus and Marshall Wace, alongside follow-on support from existing backers 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings and Platanus |
私有 | 混合(M) | 否 | ✓ | — | — | |
| 63 | Diagonal Therapeutics | 美国 | USA / Watertown, MA | Biologics | Rare diseases | Preclinical | 1 轮 | 2026-01-08 Series B $125M | 125 | Sanofi VenturesSanofi Ventures, Janus Henderson Investors / Sanofi Ventures, RA Capital Management, Atlas Venture / Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P., Woodline Partners LP, Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capi |
私有 | 自建(M) | ? | ✓ | — | — | |
| 64 | Ambros Therapeutics | 美国 | USA / Irvine CA | Biologics | CNS disorders | Phase 2 | 2 轮2025-12-16 Series A $125M2025-12-17 Series A $125M |
2025-12-17 Series A $125M | 125 | RA Capital ManagementRA Capital Management, Patient Square Capital's platform Enavate Sciences, Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners and other dedicated life sciences investors / RA Capital Management, Enavate Life Sciences / RA Capital Management |
私有 | 虚拟(M) | 否 | ✓ | — | — | |
| 65 | Sling Therapeutics | 美国 | USA / Ann Arbor, MI | Small molecules | Eye diseases | Phase 3 | 1 轮 | 2026-09-16 Series C $123M | 123 | ForbionForbion / Forbion, TPG Life Sciences Innovations and Sectoral Asset Management |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 66 | Create Medicines | 美国 | USA / Waltham, MA | Cell or gene therapy | Multiple | Phase 1 | 1 轮 | 2026-05-14 Series B $122M | 122 | Newpath PartnersNewpath Partners, Arch Venture Partners, Hatteras Venture Partners / Arch Venture Partners / Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, Alexandria Venture Investments and others |
私有 | 混合(H) | 是 | — | — | ||
| 67 | Merida Biosciences | 美国 | US / Cambridge MA | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-04-08 Series A $121M | 121 | Bain Capital Life SciencesBain Capital Life Sciences, Third Rock Ventures / Bain Capital Life Sciences, Third Rock Ventures, GV / Bain Capital Life Sciences, BVF Partners, Third Rock Ventures, GV and Perceptive Xontogeny Venture Funds (PXV Funds) |
被收购 | 自建(M) | ? | — | — | ||
| 68 | Triana Biomedicines | 美国 | US / Lexington, MA | Small molecules | Cancer | Preclinical | 1 轮 | 2025-12-03 Series B $120M | 120 | RA Capital ManagementAscenta Capital, Bessemer Venture Partners / RA Capital Management, Atlas Venture / RA Capital Management, Atlas Venture, Lightspeed Venture Partners, Pfizer Ventures, Surveyor Capital |
私有 | 自建(M) | ? | — | — | ||
| 69 | Solve Therapeutics | 美国 | USA / San Diego, CA | Biologics | Cancer | Phase 1 | 1 轮 | 2025-11-17 未披露轮 $120M | 120 | YosemiteYosemite / Alexandria Venture Investments / Yosemite, Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, General Atlantic and Citadel's Surveyor Capital |
私有 | 自建(M) | ? | — | — | ||
| 70 | Pelage Pharmaceuticals | 美国 | US / Los Angeles | Small molecules | Other | Phase 2 | 1 轮 | 2025-10-15 Series B $120M | 120 | ARCH Venture PartnersArch Venture Partners, GV / ARCH Venture Partners, GV (Google Ventures), Main Street Advisors, Visionary Ventures and YK Bioventures |
私有 | 虚拟(L) | ? | ✓ | @PelagePharma | 986 | |
| 71 | Ouro Medicines | 美国 | US / San Francisco | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-01-10 Series A $120M | 120 | TPG Life Sciences InnovationsTPG Life Science Innovations, NEA, Norwest Venture Partners / NEA / Co-led by TPG Life Sciences Innovations, NEA and Norwest Venture Partners, with Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments and other unnamed investors |
被收购 | 虚拟(H) | 是 | ✓ | — | — | |
| 72 | Claris Biotherapeutics | 美国 | USA / Jersey City, NJ | Small molecules | Eye diseases | Phase 1 | 1 轮 | 2026-07-28 Series B $118M | 118 | Samsara BioCapitalSamsara BioCapital, Catalio Capital Management / Sofinnova Investments, Novo Holdings |
私有 | 虚拟(M) | 否 | ✓ | — | — | |
| 73 | BrainChild Bio | 美国 | USA / Seattle WA | — | — | — | 1 轮 | 2026-09-08 Series A $116M | 116 | Undisclosed private family fund and founUndisclosed private family fund and foundation, Seattle Children’s and WRF Capital |
私有 | 混合(H) | 否 | — | — | ||
| 74 | ILiAD Biotechnologies | 美国 | USA / Jupiter, FL | Other | Infectious diseases | Phase 2 | 1 轮 | 2026-02-10 Series B $115M | 115 | RA Capital ManagementRA Capital Management / RA Capital Management, Janus Henderson Investors, BNP Paribas Asset Management and others |
私有 | 虚拟(M) | ? | — | — | ||
| 75 | Aspen Neuroscience | 美国 | USA / San Diego | Cell or gene therapy | CNS disorders | Phase 1 | 1 轮 | 2025-11-20 Series C $115M | 115 | OrbiMedOrbiMed, Arch Venture Partners, Frazier Life Sciences, Revelation Partners / OrbiMed, Arch Venture Partners / OrbiMed, ARCH Venture Partners, Frazier Life Sciences, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Gilead's Kite Pharma, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures and others |
私有 | 自建(H) | 否 | @AspenNeuro | 384 | ||
| 76 | Glycomine | 美国 | USA / San Carlos, CA | Small molecules | Rare diseases | Phase 2 | 1 轮 | 2025-04-16 Series C $115M | 115 | CTI Life Sciences FundCTI Life Sciences Fund, abrdn, Advent Life Sciences / Novo Holdings, Sanofi Ventures / CTI Life Sciences Fund, funds managed by abrdn, Advent Life Sciences, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures and Asahi Kasei Ventures |
私有 | 虚拟(M) | ? | — | — | ||
| 77 | Wugen | 美国 | US / St. Louis | — | — | — | 1 轮 | 2025-08-27 Series N/A $115M | 115 | Fidelity Management & Research CompanyFidelity Management & Research Company, with RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management and others |
私有 | 混合(M) | 否 | — | — | ||
| 78 | RayThera | 美国 | US / San Diego | Small molecules | Immune diseases | Preclinical | 1 轮 | 2025-04-04 Series A $110M | 110 | Foresite CapitalForesite Capital, OrbiMed / OrbiMed / Foresite Capital, OrbiMed Advisors and TTM Capital |
被收购 | 虚拟(L) | ? | — | — | ||
| 79 | Curevo | 美国 | USA / Seattle, WA | Other | Infectious diseases | Phase 2 | 1 轮 | 2025-03-17 Series B $110M | 110 | OrbiMedMedicxi / OrbiMed, RA Capital Management, Sanofi Ventures |
被收购 | 虚拟(M) | 否 | — | — | ||
| 80 | Terremoto Biosciences | 美国 | US / South San Francisco | Small molecules | Cancer | Phase 1 | 1 轮 | 2026-04-15 Series C $108M | 108 | RA Capital ManagementRA Capital, OrbiMed, Third Rock Ventures, Novo Holdings / RA Capital Management, Deep Track Capital, Osage University Partners, BeOne Medicines, OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant Asset Management |
私有 | 自建(H) | ? | — | — | ||
| 81 | EpiBiologics | 美国 | USA / South San Francisco, CA | Biologics | Multiple | Preclinical | 1 轮 | 2026-01-08 Series B $107M | 107 | Google VentureGV, Johnson & Johnson Innovation / GV, Samsara BioCapital, Polaris Partners, Vivo Capital / Google Venture, Johnson & Johnson, Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital and Mission BioCapital |
私有 | 自建(L) | ? | — | — | ||
| 82 | Profluent | 美国 | US / Emeryville | — | — | — | 1 轮 | 2025-11-19 Series N/A $106M | 106 | Altimeter CapitalAltimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners and Air Street Capital |
私有 | 混合(H) | ? | ✓ | @ProfluentBio | 4.2k | |
| 83 | Tortugas Neuroscience | 美国 | US / | — | — | — | 1 轮 | 2026-04-21 Seed/Series A $106M | 106 | Cure VenturesCure Ventures, The Column Group and AN Venture Partners |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 84 | Kinaset Therapeutics | 美国 | USA / Boston, MA | Small molecules | Other | Phase 2 | 2 轮2026-01-09 Series B $103M2026-01-10 Series B $103M |
2026-01-10 Series B $103M | 103 | RA Capital ManagementRA Capital Management / EQT Life Sciences, RA Capital Management, Atlas Venture / RA Capital Management, Forge Life Science Partners, EQT Life Sciences, Vivo Capital, Schroders Capital, Willett Advisors, Pictet Alternative Advisors, Sixty Degree Capital, Atlas Venture, 5AM Ventures and Gimv |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 85 | Neurona Therapeutics | 美国 | US / San Diego | Cell or gene therapy | CNS disorders | Phase 2 | 1 轮 | 2025-04-03 未披露轮 $102M | 102 | Fidelity Management & Research CompanyAlexandria Venture Investments / Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments and Spur Capital Partners |
被收购 | 自建(H) | ? | ✓ | — | — | |
| 86 | Ethyreal Bio | 美国 | USA / Cambridge, MA | Biologics | Eye diseases | Preclinical | 1 轮 | 2026-06-10 未披露轮 $101M | 101 | The Series A was co-led by Atlas VentureAtlas Venture, Medicxi Ventures / Atlas Venture / The Series A was co-led by Atlas Venture and Medicxi Ventures, alongside Nandi Life Sciences and Checkpoint Capital. The Series B included all Series A investors and was led by Avoro Capital |
私有 | 虚拟(L) | ? | — | — | ||
| 87 | Nilo Therapeutics | 美国 | US / New York | Undisclosed | Immune diseases | Preclinical | 1 轮 | 2025-10-08 Series A $101M | 101 | The Column GroupLux Capital, The Column Group, DCVC Bio / Alexandria Venture Investments / The Column Group, DCVC Bio, Lux Capital, the Gates Foundation and Alexandria Venture Investments |
私有 | 自建(M) | ? | — | — | ||
| 88 | City Therapeutics | 美国 | USA / Cambridge, MA | Nucleic acids | Other | Phase 1 | 1 轮 | 2026-06-08 Series B $100M | 100 | Viking Global InvestorsArch Venture Partners, Sofinnova Investments / Viking Global Investors, Sofinnova Investments, Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and others |
上市 | 混合(H) | ? | — | — | ||
| 89 | Neomorph | 美国 | US / San Diego | Small molecules | Cancer | Phase 1 | 1 轮 | 2026-04-13 Series B $100M | 100 | Deerfield ManagementDeerfield Management / Deerfield Management, Alexandria Venture Investments / Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute and others |
私有 | 自建(M) | ? | — | — | ||
| 90 | Stipple Bio | 美国 | USA / Cambridge, MA | Biologics | Cancer | Preclinical | 2 轮2026-04-06 Series A $100M2026-04-08 Series A $100M |
2026-04-08 Series A $100M | 100 | RA CapitalRA Capital Management, Nextech Invest, a16z Bio + Health / RA Capital Management, GV / RA Capital, a16z Bio+Health, Nextech Invest, Emerson Collective Investments, GV, LoLa Capital Partners and GordonMD Global Investments |
私有 | 混合(M) | 否 | — | — | ||
| 91 | Ambrosia Biosciences | 美国 | USA / Boulder CO | Small molecules | Metabolic diseases | Preclinical | 1 轮 | 2026-03-31 Series B $100M | 100 | Blue Owl Healthcare OpportunitiesBlue Owl Healthcare Opportunities, Redmile, Deep Track Capital / Samsara BioCapital / Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital, BVF Partners Boulder Ventures, Janus Henderson Investors, Samsara BioCapital and an undisclosed institutional investor |
私有 | 自建(H) | ? | — | — | ||
| 92 | Vima Therapeutics | 美国 | US / Boston | Small molecules | CNS disorders | Phase 1 | 2 轮2025-05-29 Series A $60M2026-03-12 Series A $40M |
2026-03-12 Series A $40M | 100 | Atlas VentureAtlas Venture / Atlas Venture, Access Industries and Canaan |
私有 | 虚拟(M) | ? | — | — | ||
| 93 | Avalyn Pharma | 美国 | USA / Massachusetts | Small molecules | Other | Phase 2 | 1 轮 | 2025-07-22 Series D $100M | 100 | Suvretta Capital ManagementSuvretta Capital Management, SR One / F-Prime Capital, Novo Holdings / Suvretta Capital Management, SR One, Novo Holdings, F-Prime, Perceptive Xontogeny Venture Funds, Norwest, Eventide Asset Management, Wellington Management, Vida Ventures, Catalio Capital Management, RiverVest Venture Partners, Pivotal bioVenture Partners, TPG Biotech, Hamilton Square Partners Management, LP (HSq), Rock Springs Ca |
上市 | 虚拟(H) | ? | ✓ | — | — | |
| 94 | Umoja Biopharma | 美国 | US / Boulder CO | Cell or gene therapy | Multiple | Phase 1 | 1 轮 | 2025-01-14 Series C $100M | 100 | Double Point Ventures and DCVC BioDouble Point Ventures, DCVC Bio / MPM BioImpact, Alexandria Venture Investments / Co-led by Double Point Ventures and DCVC Bio, with ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, Univ |
私有 | 自建(H) | ? | @UmojaBiopharma | 316 | ||
| 95 | Addition Therapeutics | 美国 | USA / South San Francisco | — | — | — | 1 轮 | 2025-12-17 Series N/A $100M | 100 | SR OneSR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation and BEVC |
私有 | 自建(H) | ? | — | — | ||
| 96 | Rakuten Medical | 美国 | US / San Diego | — | — | — | 1 轮 | 2026-01-07 Series F $100M | 100 | TaiAx Life Science FundTaiAx Life Science Fund, Daiwa Securities, Mitsui Sumitomo Insurance, Sumitomo Mitsui Banking, ABIES Capital, Nexus CVC, OEP Group, SBI Group, Rakuten Group and Rakuten Medical CEO Mickey Mikitani |
私有 | 混合(M) | 否 | — | — | ||
| 97 | Atalanta Therapeutics | 美国 | USA / Boston MA | Nucleic acids | CNS disorders | Preclinical | 1 轮 | 2025-01-28 Series B $97M | 97 | EQT Life SciencesEQT Life Sciences, Sanofi Ventures / EQT Life Sciences, F-Prime Capital, Sanofi Ventures / EQT Life Sciences, Sanofi Ventures, F-Prime Capital, Novartis Venture Fund, RiverVest Venture Partners, funds managed by abrdn, Pictet Alternative Advisors, the Mirae Asset Financial Group and the GHR Foundation |
私有 | 自建(M) | ? | — | — | ||
| 98 | TORL BioTherapeutics | 美国 | US / Los Angeles | — | — | — | 1 轮 | 2025-10-07 Series C $96M | 96 | Unknown | 私有 | 虚拟(M) | ? | — | — | ||
| 99 | Poplar Therapeutics | 美国 | US / Boston | Biologics | Immune diseases | Phase 1 | 2 轮2026-01-07 Series A $50M2026-03-03 Series A $45M |
2026-03-03 Series A $45M | 95 | SR OneSR One, Vida Ventures and Platanus / Janus Henderson Investors / RA Capital Management |
私有 | 虚拟(M) | ? | — | — | ||
| 100 | Sparrow Therapeutics | 美国 | US / Portland OR | Small molecules | Metabolic diseases | Phase 2 | 1 轮 | 2025-09-24 Series B $95M | 95 | RA Capital ManagementRA Capital Management, Forbion / RA Capital Management, Forbion, OrbiMed, RiverVest and US Venture Partners |
私有 | 虚拟(M) | ? | — | — | ||
| 101 | Newleos Therapeutics | 美国 | US / Boston | Small molecules | CNS disorders | Phase 1 | 1 轮 | 2025-02-13 Series A $94M | 94 | Goldman Sachs AlternativesGoldman Sachs Alternatives / Novo Holdings / Goldman Sachs Alternatives, Longwood Fund, Novo Holdings, DCVC Bio and Arkin Bio Capital |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 102 | Circle Pharma | 美国 | USA / South San Francisco, CA | Small molecules | Cancer | Phase 1 | 1 轮 | 2026-09-16 Series E $93M | 93 | The Column GroupThe Column Group / Eli Lilly and Company, RA Capital Management / The Column Group, Nextech Invest, RA Capital Management, Euclidean Capital and Eli Lilly and Company |
私有 | 混合(M) | 是 | ✓ | @CirclePharma | 73 | |
| 103 | Memento Medicines | 美国 | US / Boston | Biologics | Eye diseases | Preclinical | 1 轮 | 2026-06-18 Series A $93M | 93 | ForbionForbion, RA Capital Management, Avego BioScience Capital / Forbion, RA Capital Management, Sanofi Ventures, Samsara BioCapital / Forbion, RA Capital Management, Avego BioScience Capital, Sanofi Ventures and Samsara BioCapital |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 104 | Contraline | 美国 | USA / Charlottesville, VA | Other | Other | Phase 2 | 1 轮 | 2026-06-02 Series B $93M | 93 | BVF PartnersBVF Partners, RA Capital Management / RA Capital Management, GV / BVF Partners, RA Capital Management, Google Ventures, Lumira Ventures, Invus and others |
私有 | 自建(M) | ? | @contraline | 637 | ||
| 105 | Character Biosciences | 美国 | USA / Jersey City, NJ | — | — | — | 1 轮 | 2025-03-25 Series B $93M | 93 | aMoonaMoon, Luma Group, Bausch + Lomb, Jefferson Life Sciences, Endeavors, Catalio Capital Management, S32 and KdT Ventures |
私有 | 自建(M) | ? | — | — | ||
| 106 | Setara Biosciences | 美国 | USA / San Diego, CA | Small molecules | CNS disorders | Phase 1 | 1 轮 | 2026-10-30 Series A $90M | 90 | Deerfield Management | 私有 | 自建(L) | ? | — | — | ||
| 107 | Attovia Therapeutics | 美国 | USA / South San Francisco | Biologics | Immune diseases | Phase 1 | 1 轮 | 2025-04-15 Series C $90M | 90 | Deep Track CapitalDeep Track Capital / venBio, Sanofi Ventures / Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace and Illumina Ventures |
上市 | 混合(H) | 是 | — | — | ||
| 108 | Bambusa Therapeutics | 美国 | USA / Boston MA | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-02-14 Series A $90M | 90 | RA Capital ManagementRA Capital Management / RA Capital Management, Janus Henderson Investors, Redmile Group, Invus, ADAR1 Capital Management, and other unnamed existing investors |
上市 | 虚拟(H) | 是 | ✓ | — | — | |
| 109 | Syndeio Biosciences | 美国 | USA / Indianapolis, IN | — | — | — | 1 轮 | 2025-05-27 Series N/A $90M | 90 | Catalio Capital ManagementCatalio Capital Management, Innoviva, Tenmile, Luson Bioventures, Palo Santo, and AbbVie and Eli Lilly as strategic shareholders |
私有 | 混合(M) | ? | — | — | ||
| 110 | Pinnacle Medicines | 美国 | USA / Doylestown, PA | Biologics | Multiple | Preclinical | 1 轮 | 2026-03-26 Series B $89M | 89 | OrbiMedLAV, Foresite Capital / OrbiMed, RA Capital Management |
私有 | 混合(M) | ? | ✓ | — | — | |
| 111 | QuantX Biosciences | 美国 | US / Princeton NJ | Small molecules | Immune diseases | Preclinical | 1 轮 | 2026-02-09 Series B $85M | 85 | LAVSanofi Ventures, LAV / Sanofi Ventures / LAV, Sanofi Ventures, Hongshan and others |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 112 | Tenpoint Therapeutics | 美国 | US / | Small molecules | Other | Marketed | 2 轮2026-01-28 Series B $85M2026-01-29 Series B $85M |
2026-01-29 Series B $85M | 85 | Janus HendersonJanus Henderson Investors, EQT Nexus, Hillhouse, British Business Bank / EQT Life Sciences, Sofinnova Partners, F-Prime Capital / Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille |
私有 | 虚拟(M) | 否 | @Tenpoint_Tx | 638 | ||
| 113 | BlossomHill Therapeutics | 美国 | USA / San Diego | Small molecules | Cancer | Phase 1 | 1 轮 | 2025-12-10 Series B $84M | 84 | Janus Henderson InvestorsJanus Henderson Investors, Brahma Capital, BioTrack Capital / OrbiMed / Janus Henderson Investors, Brahma Capital, BioTrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital Management and Vivo Capital |
上市 | 混合(H) | 是 | — | — | ||
| 114 | Mendra | 美国 | US / San Francisco Bay Area | Undisclosed | Rare diseases | Preclinical | 1 轮 | 2026-01-22 Series A $82M | 82 | OrbiMedOrbiMed, 8VC, 5AM Ventures / OrbiMed / OrbiMed, 8VC, 5AM Ventures, Lux Capital and Wing VC |
私有 | 虚拟(M) | ? | ✓ | ✓ | — | — |
| 115 | Azalea Therapeutics | 美国 | USA / Berkeley CA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2025-11-04 Seed / Series A $82M | 82 | Third Rock VenturesThird Rock Ventures / Third Rock Ventures, RA Capital Management / Third Rock Ventures, RA Capital Management, Yosemite, Sozo Ventures and unnamed individual investors |
私有 | 自建(H) | ? | — | — | ||
| 116 | R1 Therapeutics | 美国 | US / Redwood City | Small molecules | Other | Phase 2 | 2 轮2026-03-17 Series A $78M2026-09-30 Series A $3M |
2026-09-30 Series A $3M | 80 | AbingworthAbingworth, F-Prime Capital, DaVita Venture Group, Curie.Bio, SymBiosis and U.S. Renal Care / Samsara BioCapital |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 117 | Proxima | 美国 | USA / New York, NY | Small molecules | Undisclosed | Preclinical | 1 轮 | 2026-01-13 Seed $80M | 80 | DCVCDCVC / Alexandria Venture Investments / DCVC, NVentures (NVIDIA’s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures and others |
私有 | 混合(M) | ? | ✓ | — | — | |
| 118 | A2 Biotherapeutics | 美国 | USA / Agoura Hills CA | Cell or gene therapy | Cancer | Phase 1 | 1 轮 | 2025-01-09 Series C $80M | 80 | A syndicate of investors that includes TSamsara BioCapital / A syndicate of investors that includes The Column Group and Samsara BioCapital |
私有 | 自建(H) | 否 | — | — | ||
| 119 | Life Biosciences | 美国 | US / Boston | — | — | — | 1 轮 | 2026-04-08 Series B $80M | 80 | Not disclosed | 私有 | 虚拟(M) | 否 | @lifebiosciences | 24k | ||
| 120 | Peptilogics | 美国 | US / Pittsburgh | — | — | — | 1 轮 | 2025-10-16 Series B2 $78M | 78 | Presight CapitalPresight Capital, Thiel Bio, Founders Fund, AMR Action Fund, Narya Capital and Beyond Ventures |
私有 | 虚拟(L) | ? | @Peptilogics | 353 | ||
| 121 | InduPro | 美国 | USA / Seattle, WA | Biologics | Cancer | Phase 1 | 1 轮 | 2026-08-12 Series B $77M | 77 | The Column GroupThe Column Group / Sanofi Ventures, Eli Lilly and Company / The Column Group, Vida Ventures, MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co., Inc.), Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company |
私有 | 自建(M) | ? | — | — | ||
| 122 | Crossbow Therapeutics | 美国 | USA / Cambridge, MA | Biologics | Cancer | Phase 1 | 1 轮 | 2026-03-18 Series B $77M | 77 | Taiho VenturesTaiho Ventures, Arkin Bio Capital / MPM BioImpact, Polaris Partners, Eli Lilly and Company / Taiho Ventures, Arkin Bio Capital, Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Mirae Asset Venture Investment |
私有 | 自建(M) | ? | — | — | ||
| 123 | Mediar Therapeutics | 美国 | US / Boston | Biologics | Immune diseases | Phase 2 | 1 轮 | 2026-01-07 Series B $76M | 76 | Amplitude VenturesAmplitude Ventures, ICG / Sofinnova Partners |
私有 | 混合(M) | 否 | ✓ | — | — | |
| 124 | BigHat Biosciences | 美国 | USA / San Mateo CA | Biologics | Cancer | Phase 1 | 1 轮 | 2026-09-24 Series C $75M | 75 | Alexandria Venture InvestmentsDFJ Growth, Premji Invest / Alexandria Venture Investments, Eli Lilly and Company |
私有 | 自建(H) | ? | ✓ | @BigHatBio | 1.2k | |
| 125 | Lycia Therapeutics | 美国 | US / South San Francisco | Biologics | Immune diseases | Preclinical | 1 轮 | 2026-06-25 Series D $75M | 75 | Janus Henderson InvestorsJanus Henderson Investors, Balyasny Asset Management / OrbiMed, Eli Lilly and Company / Janus Henderson Investors, Balyasny Asset Management, Adage Capital Management, HBM Healthcare Investments, OrbiMed, Eli Lilly, Franklin Templeton, Invus, RTW Investments and Venrock Healthcare Capital Partners |
上市 | 混合(H) | 是 | @LyciaTx | 201 | ||
| 126 | Caldera Therapeutics | 美国 | USA / Cambridge MA | Biologics | Immune diseases | Phase 1 | 1 轮 | 2026-01-14 Series A $75M | 75 | Atlas Venture, venBio | 反向并购 | 虚拟(H) | 是 | ✓ | — | — | |
| 127 | SpyGlass Pharma | 美国 | US / Aliso Viejo CA | Other | Eye diseases | Phase 2 | 1 轮 | 2025-06-02 Series D $75M | 75 | Sands CapitalSands Capital / NEA, RA Capital Management, Samsara BioCapital / Sands Capital, New Enterprise Associates, RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC |
上市 | 混合(M) | 否 | @SpyGlassPharma | 40 | ||
| 128 | Normunity | 美国 | US / Branford CT | Biologics | Cancer | Preclinical | 1 轮 | 2025-01-13 Series B $75M | 75 | Samsara BioCapital and Enavate SciencesSamsara BioCapital, Enavate Sciences / Samsara BioCapital, Sanofi Ventures / Co-led by Samsara BioCapital and Enavate Sciences, with participation from Regeneron Ventures, Pfizer Ventures, YK Bioventures, Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group and Connecticut Innovations |
私有 | 虚拟(M) | ? | @normunity | 34 | ||
| 129 | Neok Bio | 美国 | US / California (South San Francisco) | — | — | — | 1 轮 | 2025-11-03 Series A $75M | 75 | ABL Bio | 私有 | 虚拟(M) | ? | ✓ | — | — | |
| 130 | Nura Bio | 美国 | US / South San Francisco | Small molecules | CNS disorders | Phase 1 | 1 轮 | 2026-06-22 Series B $74M | 74 | The Column GroupThe Column Group / Sanofi Ventures, Samsara BioCapital / The Column Group, Euclidean Capital, Samsara BioCapital and Sanofi Ventures |
私有 | 自建(M) | ? | — | — | ||
| 131 | Arbor Biotechnologies | 美国 | USA / Cambridge MA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2025-03-18 Series C $74M | 74 | Arch Venture Partners and TCGXArch Venture Partners / Led by Arch Venture Partners and TCGX, with new investors QIA, Partners Investment, Revelation Partners and Kerna Ventures joining alongside other existing investors |
私有 | 自建(H) | ? | @arbortx | 551 | ||
| 132 | Moonwalk Biosciences | 美国 | US / South San Francisco | Nucleic acids | Metabolic diseases | Preclinical | 1 轮 | 2026-09-08 Series B $70M | 70 | Alpha WaveArch Venture Partners, Eli Lilly and Company / Alpha Wave, YK Bioventures, Eli Lilly, Gaorong Ventures, Arch Venture Partners, Khosla Ventures and Future Ventures |
私有 | 混合(M) | 是 | @moonwalkbio | 17 | ||
| 133 | Ratio Therapeutics | 美国 | US / Boston | Radiopharmaceuticals | Cancer | Phase 1 | 1 轮 | 2026-07-31 Series C $70M | 70 | Duquesne Family OfficeEli Lilly and Company / Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company and Wasatch Group |
私有 | 混合(H) | 否 | @Ratio_Tx | 138 | ||
| 134 | Prolynx | 美国 | US / San Francisco Bay Area | Biologics | Metabolic diseases | Preclinical | 1 轮 | 2025-12-11 Series A $70M | 70 | 5AM Ventures5AM Ventures, OrbiMed / OrbiMed / 5AM Ventures, OrbiMed and Monograph Capital |
私有 | 混合(H) | 否 | — | — | ||
| 135 | Excelsior Sciences | 美国 | USA / New York, NY | Small molecules | Undisclosed | Preclinical | 1 轮 | 2025-12-03 Series A $70M | 70 | Deerfield ManagementDeerfield Management, Khosla Ventures, Sofinnova Partners / Deerfield Management, Sofinnova Partners, Eli Lilly and Company |
私有 | 自建(H) | 否 | ✓ | — | — | |
| 136 | Excellergy | 美国 | USA / California (Bay Area) | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-10-13 Series A $70M | 70 | Samsara BioCapitalSamsara BioCapital / Samsara BioCapital, Red Tree Venture Capital and Decheng Capital |
被收购 | 虚拟(M) | ? | — | — | ||
| 137 | Tempero Bio | 美国 | US / California | — | — | — | 1 轮 | 2025-03-24 Series B $70M | 70 | 8VC8VC, Aditum Bio, Khosla Ventures and other unnamed investors |
不明 | 虚拟(M) | ? | ✓ | — | — | |
| 138 | XyloCor Therapeutics | 美国 | USA / King of Prussia, PA | Cell or gene therapy | Other | Phase 2 | 1 轮 | 2025-01-07 Series B $68M | 68 | New investor Jeito CapitalJeito Capital / EQT Life Sciences / New investor Jeito Capital and existing institutional investors EQT, Fountain Healthcare Partners and Lumira Ventures |
私有 | 虚拟(M) | ? | — | — | ||
| 139 | Fore Biotherapeutics | 美国 | USA / Philadelphia, PA | Small molecules | Cancer | Phase 2 | 1 轮 | 2026-07-07 Series D $67M | 67 | SR One, Medicxi, SymBiosis / OrbiMed | 私有 | 虚拟(H) | ? | @ForeBiotx | 90 | ||
| 140 | Hillstar Bio | 美国 | USA / Boston, MA | Biologics | Immune diseases | Preclinical | 2 轮2025-03-25 Series A $67M2025-03-26 Series A $67M |
2025-03-26 Series A $67M | 67 | Droia VenturesDroia Ventures, Frazier Life Sciences, Novo Holdings, LifeArc Ventures and Hummingbird Bioscience / Novo Holdings, Droia Ventures, Frazier Life Sciences, LifeArc Ventures, Hummingbird Bioscience / Novo Holdings |
私有 | 自建(H) | ? | — | — | ||
| 141 | Cartography Biosciences | 美国 | USA / South San Francisco | — | — | — | 1 轮 | 2025-10-02 Series B $67M | 67 | Pfizer VenturesPfizer Ventures, LG Corp, Amgen Ventures, Finchley H.V., Global BioAccess Fund, Lotte Holdings CVC, Andreessen Horowitz (a16z) Bio + Health, 8VC, Wing Venture Capital, Catalio Capital Management, AME Cloud Ventures, ARTIS Ventures and Gaingels |
私有 | 自建(H) | ? | ✓ | @CartographyBio | 478 | |
| 142 | Actio Biosciences | 美国 | USA / San Diego | Small molecules | Rare diseases | Phase 1 | 1 轮 | 2025-06-18 Series B $66M | 66 | Regeneron VenturesRegeneron Ventures, Deerfield Management / Deerfield Management / Regeneron Ventures, Deerfield Management, Canaan, Droia Ventures and Euclidean Capital |
被收购 | 自建(M) | ? | — | — | ||
| 143 | RegCell | 美国 | USA / Emeryville, CA | — | — | — | 1 轮 | 2026-09-15 A and grant funding $66M | 66 | Playground GlobalPlayground Global, Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures, Medical Incubator Japan, Fast Track Initiative, The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Kyoto iCAP and Japan’s Agency for Medical Research and Development |
私有 | 自建(L) | ? | — | — | ||
| 144 | Boulevard Bio | 美国 | USA / New York, NY | Biologics | Immune diseases | Phase 1 | 1 轮 | 2026-08-12 未披露轮 $65M | 65 | Deerfield Management | 私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 145 | Gate Bioscience | 美国 | USA / Brisbane, CA | Small molecules | Multiple | Preclinical | 1 轮 | 2025-11-13 Series B $65M | 65 | ForbionForbion / Forbion, Eli Lilly and Company, Versant Ventures, Arch Venture Partners, GV / Forbion, Eli Lilly, Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV and ARCH Venture Partners |
私有 | 自建(M) | ? | — | — | ||
| 146 | Dualitas | 美国 | USA / South San Francisco, CA | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-09-16 Series A $65M | 65 | Versant VenturesVersant Ventures, Qiming Venture Partners USA / Versant Ventures, Alexandria Venture Investments, Eli Lilly and Company / Versant Ventures, Qiming Venture Partners USA, SV Health Investors, Chugai Venture Fund, Eli Lilly and Alexandria Venture Investments |
私有 | 自建(M) | ? | — | — | ||
| 147 | Helicore Biopharma | 美国 | USA / California | Biologics | Metabolic diseases | Preclinical | 1 轮 | 2025-01-28 Series A $65M | 65 | Founding investor Versant VenturesVersant Ventures, OrbiMed / Founding investor Versant Ventures, OrbiMed, Longitude Capital and Wellington Management |
不明 | 虚拟(M) | ? | — | — | ||
| 148 | Ampersand Biomedicines | 美国 | USA / Cambridge MA | — | — | — | 1 轮 | 2025-03-19 Series B $65M | 65 | Flagship PioneeringFlagship Pioneering, Eli Lilly and additional unnamed new investors |
私有 | 自建(H) | ? | ✓ | @AmpersandBio | 118 | |
| 149 | Triveni Bio | 美国 | US / Watertown MA | — | — | — | 1 轮 | 2026-06-17 Series C $65M | 65 | Ascenta Capital and Janus Henderson InveAscenta Capital and Janus Henderson Investors, with participation from Deep Track Capital and existing investors |
私有 | 自建(H) | ? | — | — | ||
| 150 | TwoStep Therapeutics | 美国 | USA / San Carlos, CA | — | — | — | 1 轮 | 2026-09-09 Series A $62M | 62 | Insight PartnersInsight Partners, Medical Excellence Capital, M Ventures (the venture capital arm of Merck KGaA), Pfizer Ventures, NFX, 2048 Ventures, Stanford University and others |
私有 | 自建(L) | ? | — | — | ||
| 151 | Oblenio Bio | 美国 | US / Cambridge MA | Biologics | Immune diseases | Preclinical | 1 轮 | 2026-06-25 Series B $62M | 62 | Pfizer VenturesPfizer Ventures / GV / Pfizer Ventures, Deep Track Capital, GV and Aditum Bio |
私有 | 虚拟(H) | 是 | ✓ | — | — | |
| 152 | Light Horse Therapeutics | 美国 | USA / San Diego, CA | Small molecules | Cancer | Preclinical | 1 轮 | 2025-01-09 Series A $62M | 62 | Versant VenturesVersant Ventures / Versant Ventures, Mubadala Capital, Bristol Myers Squibb, Taiho Ventures and AbbVie |
私有 | 自建(M) | ? | — | — | ||
| 153 | Plexium | 美国 | US / San Diego | — | — | — | 1 轮 | 2025-08-28 Series N/A $60M | 60 | N/A | 私有 | 混合(H) | 是 | ✓ | @PlexiumInc | 1 | |
| 154 | Superluminal Medicines | 美国 | US / Boston | Small molecules | Metabolic diseases | Preclinical | 1 轮 | 2026-09-03 Series B $60M | 60 | BVF Partners L.PBVF Partners / RA Capital Management, Eli Lilly and Company / BVF Partners L.P., Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels |
私有 | 混合(H) | ? | @superluminalrx | 7 | ||
| 155 | Link Cell Therapies | 美国 | US / California (Bay Area) | Cell or gene therapy | Cancer | Preclinical | 1 轮 | 2025-12-15 Series A $60M | 60 | Samsara BioCapitalJohnson & Johnson Innovation / Samsara BioCapital / Samsara BioCapital, Sheatree Capital, Johnson & Johnson Innovation, Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital and Sherpa Healthcare Partners |
私有 | 混合(M) | 是 | — | — | ||
| 156 | Avenzo Therapeutics | 美国 | USA / San Diego | Small molecules | Cancer | Phase 1 | 1 轮 | 2025-09-22 Series B $60M | 60 | OrbiMedOrbiMed, SR One / OrbiMed, NEA / OrbiMed, SR One, Longwood Fund, Foresite Capital, Lilly Asia Ventures, Surveyor Capital (a Citadel company), New Enterprise Associates, Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital and Quan Capital |
反向并购 | 虚拟(H) | 是 | ✓ | — | — | |
| 157 | Gilgamesh Pharma | 美国 | USA / New York, NY | — | — | — | 1 轮 | 2026-03-25 Series A $60M | 60 | Satori Neuro plus newSatori Neuro plus new and existing institutional investors including Prime Movers Lab |
私有 | 虚拟(H) | 是 | ✓ | — | — | |
| 158 | BreezeBio | 美国 | USA / South San Francisco CA | — | — | — | 1 轮 | 2026-02-25 Series B $60M | 60 | Yuanta InvestmentYuanta Investment, DSC Investment, SV investment, Kiwoom Investment, STIC Ventures, Top Harvest Capital, DAYLI Partners, Pathway Investment, Loftyrock Investment, Korea Investment Partners, WOORI Venture Partners, KDB Silicon Valley and ACVC Partners |
私有 | 自建(H) | ? | — | — | ||
| 159 | Breakthru Medicine | 美国 | USA / Phoenix AZ | — | — | — | 1 轮 | 2026-01-29 Series A $60M | 60 | N/A | 私有 | 虚拟(M) | ? | ✓ | — | — | |
| 160 | Cytotheryx | 美国 | USA / Minnesota | — | — | — | 2 轮2026-01-12 Series A $60M2026-01-16 Series A $60M |
2026-01-16 Series A $60M | 60 | Ouroboros Family Founders Fund IOuroboros Family Founders Fund I / Ouroboros Family Founders Fund I, LP |
私有 | 自建(H) | 否 | — | — | ||
| 161 | Allay Therapeutics | 美国 | USA / Burlingame CA | Small molecules | CNS disorders | Phase 2 | 1 轮 | 2025-06-05 Series D $58M | 58 | Lightstone VenturesLightstone Ventures, ClavystBio / NEA / Lightstone Ventures, ClavystBio, NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, Brandon Capital, IPD Capital, EDBI and SGInnovate, and HSBC Innovation Banking |
私有 | 自建(M) | 否 | @allaytx | 33 | ||
| 162 | Imbria Pharmaceuticals | 美国 | USA / Boston, MA | Small molecules | Other | Phase 2 | 1 轮 | 2025-04-10 Series B $58M | 58 | Deep Track CapitalDeep Track Capital / RA Capital Management / Deep Track Capital, AN Ventures, Catalio Capital Management, Cytokinetics, RA Capital Management and SV Health Investors |
私有 | 虚拟(H) | ? | @ImbriaPharma | 45 | ||
| 163 | Typewriter Therapeutics | 美国 | US / Cambridge MA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2026-09-02 Series A $56M | 56 | AN Venture PartnersAN Venture Partners, RA Capital Management / RA Capital Management |
私有 | 自建(M) | ? | — | — | ||
| 164 | Tectora Therapeutics | 美国 | US / | Small molecules | Immune diseases | Preclinical | 1 轮 | 2026-09-09 Series A $55M | 55 | New Enterprise Associates and RA CapitalRA Capital Management, NEA / New Enterprise Associates and RA Capital Management |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 165 | Aeovian Pharmaceuticals | 美国 | USA / Pasadena CA | Small molecules | CNS disorders | Phase 1 | 1 轮 | 2025-12-16 Series B $55M | 55 | Luma Group. CTI Life Sciences FundLuma Group, CTI Life Sciences Fund / Sofinnova Investments, venBio / Luma Group. CTI Life Sciences Fund, Foresite Capital, SymBiosis, the TSC Alliance Endowment Fund, Wilson Sonsini, Apollo Health Ventures, Hevolution, Sofinnova Investments and venBio |
私有 | 虚拟(M) | ? | — | — | ||
| 166 | Renasant Bio | 美国 | US / California | Small molecules | Other | Preclinical | 1 轮 | 2025-07-10 Seed $55M | 55 | 5 AM Ventures5 AM Ventures, Atlas Venture, OrbiMed, Qiming Venture Partners USA / Atlas Venture, OrbiMed / 5AM Ventures, Atlas Venture, OrbiMed and Qiming Ventures |
私有 | 自建(M) | ? | — | — | ||
| 167 | Think Bioscience | 美国 | US / Colorado | — | — | — | 1 轮 | 2026-01-21 Series A $55M | 55 | Regeneron VenturesRegeneron Ventures, Innovation Endeavors, Janus Henderson Investors, T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures, AV8 Ventures, CU Innovations and Buff Gold Ventures |
私有 | 自建(H) | ? | — | — | ||
| 168 | SciNeuro Pharmaceuticals | 美国 | USA / Rockville, MD | Multiple | CNS disorders | Phase 1 | 1 轮 | 2025-12-04 未披露轮 $53M | 53 | LAVArch Venture Partners, LAV / Arch Venture Partners / LAV, ARCH Venture Partners, plus new and existing investors |
私有 | 混合(M) | ? | ✓ | — | — | |
| 169 | Arnatar Therapeutics | 美国 | USA / San Diego | — | — | — | 1 轮 | 2025-08-25 Series A $52M | 52 | Eight Roads and 3E BioventuresEight Roads and 3E Bioventures, along with F-Prime Capital, Zhuhai Huajin Capital, Legend Star, Transfar Capital, New Alliance Capital, Yijing Capital, Gaorong Ventures, Jifeng Ventures and Hongsheng Capital |
私有 | 混合(H) | 是 | — | — | ||
| 170 | Third Arc Bio | 美国 | US / | — | — | — | 1 轮 | 2026-02-04 A extension $52M | 52 | additional investors include Life SciencNew investor Andreessen Horowitz (a16z) leads the extension with Omega Funds / additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners, funds managed by abrdn, accounts advised by T. Rowe Price Associates, Marshall Wace, Hillhouse Investment, Galapagos, AbbVie Ventures and Alderline Group |
私有 | 虚拟(H) | 否 | — | — | ||
| 171 | Caspian Therapeutics | 美国 | USA / San Diego | Small molecules | Metabolic diseases | Preclinical | 1 轮 | 2026-09-09 Series A $50M | 50 | BVF PartnersEli Lilly and Company / BVF Partners, T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of Kura’s leadership team and several other biotech entrepreneurs |
私有 | 虚拟(M) | ? | — | — | ||
| 172 | Khartis Therapeutics | 美国 | USA / San Diego, CA | Small molecules | Immune diseases | Preclinical | 1 轮 | 2026-08-13 Series B $50M | 50 | Alexandria Venture InvestmentsForge Life Science Partners / Alexandria Venture Investments |
私有 | 不明(L) | ? | — | — | ||
| 173 | Serif Biomedicines | 美国 | US / Cambridge MA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2026-04-21 未披露轮 $50M | 50 | Flagship Pioneering | 私有 | 自建(M) | ? | ✓ | — | — | |
| 174 | TRexBio | 美国 | US / San Francisco | Biologics | Immune diseases | Phase 1 | 1 轮 | 2026-01-27 Series B $50M | 50 | Janus Henderson InvestorsEli Lilly and Company, Polaris Partners / Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris Partners and SV Health Investors |
上市 | 混合(H) | ? | — | — | ||
| 175 | AllRock Bio | 美国 | USA / Natick MA | Small molecules | Other | Phase 1 | 1 轮 | 2025-09-16 Series A $50M | 50 | Versant VenturesVersant Ventures, Westlake Village BioPartners / Versant Ventures / Versant Ventures and Westlake BioPartners |
私有 | 虚拟(M) | 否 | ✓ | — | — | |
| 176 | Sirius Therapeutics | 美国 | USA / San Diego, CA | Nucleic acids | Metabolic diseases | Phase 1 | 1 轮 | 2025-05-09 Series B $50M | 50 | OrbiMed | IPO申请 | 虚拟(H) | 是 | — | — | ||
| 177 | Etiome | 美国 | USA / Cambridge, MA | Undisclosed | Multiple | Preclinical | 1 轮 | 2025-04-24 Series A $50M | 50 | Flagship Pioneering | 私有 | 自建(M) | ? | ✓ | — | — | |
| 178 | Garuda Therapeutics | 美国 | USA / Cambridge, MA | Cell or gene therapy | Other | Preclinical | 1 轮 | 2025-03-04 Series A $50M | 50 | OrbiMedOrbiMed / OrbiMed, Northpond Ventures, Cormorant Asset Management and Kyowa Kirin |
私有 | 自建(M) | ? | @GarudaTx | 47 | ||
| 179 | Tr1X | 美国 | US / San Diego | — | — | — | 1 轮 | 2025-10-14 Series N/A $50M | 50 | Unnamed existing investors | 私有 | 自建(M) | 否 | — | — | ||
| 180 | OncoC4 | 美国 | US / Rockville MD | — | — | — | 1 轮 | 2025-10-02 Series B $50M | 50 | GBA FundGBA Fund, HM Capital, 3E Bioventures Capital and Kaitai Capital |
私有 | 混合(M) | 是 | ✓ | — | — | |
| 181 | Prolium Bioscience | 美国 | US / New York | — | — | — | 1 轮 | 2026-03-03 Series A $50M | 50 | RTW Investments | 私有 | 虚拟(M) | ? | ✓ | — | — | |
| 182 | PsiThera | 美国 | US / Watertown MA | Undisclosed | Immune diseases | Preclinical | 1 轮 | 2025-12-10 Series A $48M | 48 | Samsara BioCapitalSamsara BioCapital, Lightstone Ventures / Samsara BioCapital |
私有 | 自建(H) | ? | ✓ | — | — | |
| 183 | Fathom Therapeutics | 美国 | USA / New York, NY | Small molecules | Undisclosed | Preclinical | 1 轮 | 2026-04-27 Series A $47M | 47 | Alexandria Venture InvestmentsSutter Hill Ventures / Alexandria Venture Investments |
私有 | 虚拟(L) | ? | ✓ | — | — | |
| 184 | Lifordi Immunotherapeutics | 美国 | US / Burlington MA | Biologics | Immune diseases | Phase 1 | 1 轮 | 2025-11-18 未披露轮 $42M | 42 | Sanofi VenturesSanofi Ventures, Arch Venture Partners, Atlas Venture |
私有 | 混合(M) | ? | — | — | ||
| 185 | Solu Therapeutics | 美国 | USA / Boston, MA | Biologics | Cancer | Preclinical | 1 轮 | 2025-04-05 Series A $41M | 41 | Alexandria Venture InvestmentsAlexandria Venture Investments, Eli Lilly and Company |
私有 | 自建(M) | ? | @Solu_Tx | 37 | ||
| 186 | Alloy Therapeutics | 美国 | USA / Waltham MA | Drug discovery | Multiple | Phase 3 | 1 轮 | 2026-04-15 Series E $40M | 40 | Alexandria Venture Investments | 私有 | 自建(H) | ? | ✓ | @AlloyTx | 230 | |
| 187 | Affinia Therapeutics | 美国 | USA / Waltham MA | Cell or gene therapy | Other | Preclinical | 1 轮 | 2025-10-07 Series C $40M | 40 | NEANEA / NEA, Atlas Venture, Alexandria Venture Investments, GV, Eli Lilly and Company |
私有 | 自建(M) | ? | @AffiniaTx | 0 | ||
| 188 | Therini Bio | 美国 | USA / South San Francisco, CA | Biologics | Multiple | Phase 1 | 1 轮 | 2025-05-14 Series A $39M | 39 | Eli Lilly and Company, Sanofi Ventures | 私有 | 虚拟(H) | 否 | — | — | ||
| 189 | Vivace Therapeutics | 美国 | US / San Mateo CA | Small molecules | Cancer | Phase 1 | 1 轮 | 2025-03-12 Series D $35M | 35 | RA Capital Management | 私有 | 虚拟(M) | 是 | — | — | ||
| 190 | Northlinks Bio | 美国 | US / Boston | Small molecules | Infectious diseases | Phase 2 | 1 轮 | 2026-06-23 未披露轮 $34M | 34 | RA Capital Management | 私有 | 虚拟(H) | 否 | — | — | ||
| 191 | Cloverleaf Bio | 美国 | USA / New Haven, CT | Nucleic acids | Cancer | Preclinical | 1 轮 | 2026-09-08 Seed $33M | 33 | 4BIO Capital / Eli Lilly and Company | 私有 | 自建(M) | ? | @cloverleafbio | 26 | ||
| 192 | Oak Hill Bio | 美国 | USA / Morristown, NJ | Nucleic acids | Rare diseases | Phase 2 | 1 轮 | 2026-06-01 Series A $33M | 33 | Balyasny Asset ManagementBalyasny Asset Management, venBio, Janus Henderson Investors / venBio |
私有 | 虚拟(H) | ? | ✓ | — | — | |
| 193 | Secretome Therapeutics | 美国 | USA / Plano, TX | Cell or gene therapy | Rare diseases | Preclinical | 1 轮 | 2026-05-28 Series A $30M | 30 | RA Capital Management | 私有 | 混合(M) | 否 | @SecretomeTx | 16 | ||
| 194 | Grove Biopharma | 美国 | USA / Chicago, IL | Biologics | Multiple | Preclinical | 1 轮 | 2025-04-23 Series A $30M | 30 | DCVC Bio / Eli Lilly and Company | 私有 | 自建(H) | ? | — | — | ||
| 195 | Auron Therapeutics | 美国 | USA / Boston MA | Small molecules | Cancer | Preclinical | 1 轮 | 2025-02-04 Series B $27M | 27 | DCVC Bio / Polaris Partners | 私有 | 混合(M) | 否 | ✓ | — | — | |
| 196 | AeroRx Therapeutics | 美国 | USA / La Jolla CA | Small molecules | Other | Phase 2 | 1 轮 | 2025-10-07 Series A $21M | 21 | Alexandria Venture InvestmentsAvalon BioVentures / Alexandria Venture Investments |
私有 | 虚拟(H) | ? | — | — | ||
| 197 | Tavo Biotherapeutics | 美国 | USA / Laguna Beach, CA | Biologics | Eye diseases | Phase 1 | 1 轮 | 2026-06-02 Series A $17M | 17 | Pureos Bioventures / Polaris Partners | 私有 | 虚拟(M) | ? | — | — | ||
| 198 | Perceive Pharma | 美国 | US / San Francisco | Biologics | Other | Preclinical | 1 轮 | 2025-02-18 Series A $15M | 15 | Deerfield Management | 私有 | 不明(L) | ? | — | — | ||
| 199 | Cirrus Therapeutics | 美国 | USA / Cambridge, MA | Cell or gene therapy | Eye diseases | Preclinical | 1 轮 | 2025-10-02 Seed $11M | 11 | ClavystBio / Polaris Partners | 私有 | 混合(M) | 否 | — | — | ||
| 200 | Remedium Bio | 美国 | USA / Needham, MA | Cell or gene therapy | Multiple | Preclinical | 1 轮 | 2026-08-10 Series A $10M | 10 | Lifespan Vision VenturesLifespan Vision Ventures / Eli Lilly and Company |
私有 | 虚拟(M) | 否 | — | — | ||
| 201 | Be Biopharma | 美国 | USA / Cambridge MA | Cell or gene therapy | Other | Phase 1 | 1 轮 | 2025-01-15 Series C $10M | 10 | Arch Venture PartnersNextech / Arch Venture Partners, Atlas Venture, RA Capital Management |
私有 | 混合(M) | 否 | — | — | ||
| 202 | Isomorphic Labs | 欧洲 | UK / London | Drug discovery | Undisclosed | Preclinical | 2 轮2025-03-31 未披露轮 $600M2026-05-12 Series B $2100M |
2026-05-12 Series B $2100M | 2700 | Thrive CapitalThrive Capital / GV / Led by Thrive Capital with participation from Google’s GV and follow-on capital from Alphabet / Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund |
私有 | 虚拟(H) | ? | ✓ | @IsomorphicLabs | 66k | |
| 203 | Verdiva Bio | 欧洲 | UK / London | Biologics | Metabolic diseases | Phase 1 | 1 轮 | 2025-01-09 Series A $411M | 411 | Forbion and General AtlanticForbion, General Atlantic / Forbion, RA Capital Management, OrbiMed / Co-led by Forbion and General Atlantic, with RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 204 | Windward Bio | 欧洲 | Switzerland / Basel | Biologics | Immune diseases | Phase 1 | 2 轮2025-01-10 Series A $200M2026-05-04 Crossover $165M |
2026-05-04 Crossover $165M | 365 | OrbiMedOrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities / OrbiMed, Novo Holdings / Led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital and Pivotal bioVenture Partners / OrbiMed / OrbiMed, RA Capital Management, Novo Holdings, Sanofi Ventures |
IPO申请 | 虚拟(H) | 是 | ✓ | — | — | |
| 205 | Tubulis | 欧洲 | Germany / Munich | Biologics | Cancer | Phase 1 | 1 轮 | 2025-10-15 Series C $361M | 361 | Venrock Healthcare Capital PartnersVenrock Healthcare Capital Partners / EQT Life Sciences / Venrock Healthcare Capital Partners, Wellington Management, Ascenta Capital, Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT and Seventure Partners |
被收购 | 混合(H) | 是 | — | — | ||
| 206 | CellCentric | 欧洲 | UK / Cambridge | Small molecules | Cancer | Phase 2 | 2 轮2025-05-19 Series C $120M2026-05-06 Series D $220M |
2026-05-06 Series D $220M | 340 | RA Capital ManagementRA Capital, Forbion / RA Capital Management, Forbion, Avego Bioscience Capital, and the American Cancer Society’s venture capital arm / Venrock / Sofinnova Partners, RA Capital Management, Forbion |
私有 | 虚拟(M) | 是 | @CellCentric | 699 | ||
| 207 | OMass Therapeutics | 欧洲 | UK / Oxford | Small molecules | Multiple | Phase 1 | 1 轮 | 2026-10-15 Series C $310M | 310 | Novo HoldingsNovo Holdings, Bain Capital Life Sciences, Forbion / Novo Holdings, Bain Capital Life Sciences, Forbion, GV, Sanofi Ventures |
私有 | 自建(H) | ? | @omasstx | 595 | ||
| 208 | Draig Therapeutics | 欧洲 | UK / Cardiff | Small molecules | CNS disorders | Phase 1 | 2 轮2025-06-18 Series A $140M2026-07-14 Series B $65M |
2026-07-14 Series B $65M | 205 | Access BiotechnologyAccess Biotechnology / Sanofi Ventures / Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures, Schroders Capital, SV Health Investors, and ICG / Deep Track Capital, Janus Henderson Investors, Marshall Wace, British Business Bank and Jefferson Life Sciences |
私有 | 虚拟(M) | ? | — | — | ||
| 209 | Bionyra | 欧洲 | France / Paris | Biologics | Immune diseases | Phase 1 | 1 轮 | 2026-06-22 Series A $165M | 165 | Sofinnova PartnersJeito Capital, Sofinnova Partners / Sofinnova Partners, Sanofi Ventures |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 210 | Hemab Therapeutics | 欧洲 | Denmark / Copenhagen | Biologics | Rare diseases | Phase 2 | 1 轮 | 2025-10-27 Series C $157M | 157 | Sofinnova PartnersSofinnova Partners / Sofinnova Partners, RA Capital Management, Novo Holdings / Sofinnova Partners, Avoro Capital Advisors, RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro Ventures, Maj Invest Equity, Rock Springs Capital and an unnamed global asset management company |
上市 | 混合(M) | 是 | @Hemab_Tx | 200 | ||
| 211 | Vaderis Therapeutics | 欧洲 | Switzerland / Basel | Small molecules | Rare diseases | Phase 3 | 1 轮 | 2026-08-11 Series B $152M | 152 | Life Sciences at Goldman Sachs AlternatiLife Sciences at Goldman Sachs Alternatives, TCGX / EQT Life Sciences / Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi and Droia |
私有 | 虚拟(M) | ? | — | — | ||
| 212 | Azafaros | 欧洲 | Netherlands / Leiden | Small molecules | Rare diseases | Phase 2 | 1 轮 | 2025-05-13 Series B $147M | 147 | Jeito CapitalJeito Capital, Forbion / Forbion / Jeito Capital, Forbion Growth, Seroba, Pictet Group, Forbion Ventures, Schroders Capital and BioGeneration Ventures |
私有 | 虚拟(M) | ? | — | — | ||
| 213 | AAVantgarde | 欧洲 | Italy / Milan | Cell or gene therapy | Eye diseases | Phase 1 | 1 轮 | 2025-11-03 Series B $141M | 141 | Schroders CapitalSchroders Capital, Atlas Venture, Forbion / Atlas Venture, Forbion / Schroders Capital, Atlas Venture, Forbion, Amgen Ventures, Athos Capital, CDP Venture Capital through its Large Ventures Fund, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, Willett Advisors, Longwood Fund and Sofinnova Partners |
私有 | 混合(M) | 否 | — | — | ||
| 214 | Basecamp Research | 欧洲 | UK / London | — | — | — | 1 轮 | 2026-09-23 Series C $140M | 140 | S32S32, Anthropic's Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures |
私有 | 自建(M) | 否 | ✓ | @Basecamp_Res | 1.9k | |
| 215 | Nouscom | 欧洲 | Switzerland / Basel | Vaccines | Infectious diseases | Phase 1 | 1 轮 | 2026-10-19 Series D $135M | 135 | EQT Life SciencesM Ventures, Revelation Partners / EQT Life Sciences, Versant Ventures |
私有 | 混合(M) | 否 | — | — | ||
| 216 | SpliceBio | 欧洲 | Spain / Barcelona | Cell or gene therapy | Eye diseases | Phase 1 | 1 轮 | 2025-06-11 Series B $135M | 135 | EQT Life SciencesEQT Life Sciences, Sanofi Ventures / EQT Life Sciences, NEA, Sanofi Ventures / EQT Life Sciences, Sanofi Ventures, Roche Venture Fund, New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund and Asabys Partners |
私有 | 自建(M) | ? | @SpliceBioHQ | 325 | ||
| 217 | Artbio | 欧洲 | Norway / Oslo | Radiopharmaceuticals | Cancer | Phase 0 | 1 轮 | 2025-07-29 Series B $132M | 132 | Sofinnova InvestmentsSofinnova Investments, B Capital / Sofinnova Investments, F-Prime Capital, Third Rock Ventures, Alexandria Venture Investments / Sofinnova Investments, B Capital and a life sciences fund that invested previously, along with existing investors F-Prime, Omega Funds and Third Rock Ventures and new investors Qatar Investment Authority and Alexandria Venture Investments |
私有 | 混合(M) | 否 | — | — | ||
| 218 | GlycoEra | 欧洲 | Switzerland / Schlieren (Zurich) | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-05-27 Series B $130M | 130 | Sofinnova PartnersNovo Holdings / Sofinnova Partners, Novo Holdings |
私有 | 自建(M) | ? | — | — | ||
| 219 | Coultreon Biopharma | 欧洲 | Belgium / Leuven | Small molecules | Immune diseases | Phase 1 | 1 轮 | 2026-04-28 Series A $125M | 125 | Sofinnova InvestmentsSofinnova Investments, Forbion, Novo Holdings / Sofinnova Investments, Forbion, Novo Holdings, Samsara BioCapital / Sofinnova Investments, Forbion, Novo Holdings, Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures |
私有 | 虚拟(L) | ? | ✓ | — | — | |
| 220 | Adcytherix | 欧洲 | France / Paris | Biologics | Cancer | Preclinical | 1 轮 | 2025-10-16 Series A $122M | 122 | BpifranceBpifrance, Kurma Partners, Andera Partners, Angelini Ventures / RA Capital Management / Bpifrance, Kurma Partners, Andera Partners, Angelini Ventures, Citadel's Surveyor Capital, aMoon and existing investors |
私有 | 虚拟(M) | 是 | — | — | ||
| 221 | RQ Bio | 欧洲 | UK / London | Biologics | Infectious diseases | Preclinical | 1 轮 | 2026-06-24 Series A $115M | 115 | Frazier Life SciencesFrazier Life Sciences / EQT Life Sciences, Forbion / Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, LifeArc Ventures, Oxford Science Enterprises and the University of Oxford |
私有 | 混合(M) | 否 | — | — | ||
| 222 | Artios Pharma | 欧洲 | UK / Cambridge | Biologics | Cancer | Phase 2 | 1 轮 | 2025-11-17 Series D $115M | 115 | SV Health InvestorsSV Health Investors, RA Capital Management / RA Capital Management, Sofinnova Partners, EQT Life Sciences / SV Health Investors, RA Capital Management, Janus Henderson Investors and unnamed existing investors |
私有 | 混合(M) | ? | @artiospharma | 796 | ||
| 223 | Granite Bio | 欧洲 | Switzerland / Basel | — | — | — | 1 轮 | 2025-04-24 A & B $100M | 100 | Versant VenturesVersant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures |
私有 | 虚拟(M) | ? | — | — | ||
| 224 | Nuclidium | 欧洲 | Switzerland / Basel | — | — | — | 1 轮 | 2025-07-10 Series B $99M | 99 | Kurma Growth Opportunities FundKurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, Neva SGR (Intesa Sanpaolo Group), DeepTech & Climate Fonds, Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK, HighLight Capital, plus other unnamed existing investors |
私有 | 虚拟(M) | 否 | — | — | ||
| 225 | NanoPhoria Biosciences | 欧洲 | Italy / Milan | Biologics | Other | Preclinical | 1 轮 | 2025-10-06 Series A $97M | 97 | XGEN VentureXGEN Venture, Sofinnova Partners, CDP Venture Capital / Sofinnova Partners |
私有 | 虚拟(M) | ? | — | — | ||
| 226 | Trogenix | 欧洲 | UK / Glasgow | Cell or gene therapy | Cancer | Preclinical | 1 轮 | 2025-10-06 Series A $95M | 95 | IQ Capital / Eli Lilly and Company | 私有 | 虚拟(L) | ? | — | — | ||
| 227 | Orbis Medicines | 欧洲 | Denmark / Copenhagen | Biologics | Undisclosed | Preclinical | 1 轮 | 2025-01-06 Series A $93M | 93 | NEA (New Enterprise Associates)NEA / Forbion, NEA, Eli Lilly and Company, Novo Holdings / NEA (New Enterprise Associates), Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion |
私有 | 自建(H) | ? | ✓ | — | — | |
| 228 | AnaCardio | 欧洲 | Sweden / Stockholm | Small molecules | Other | Phase 1 | 2 轮2025-01-09 Series A $19M2026-09-30 Series B $71M |
2026-09-30 Series B $71M | 90 | Novo HoldingsNovo Holdings, Pureos Bioventures, Sound Bioventures / Novo Holdings / Novo Holdings, Ljungström family office / Novo Holdings, the Ljungström family office, Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB and Innovestor Life Science |
私有 | 虚拟(H) | ? | ✓ | — | — | |
| 229 | Immutrin | 欧洲 | UK / Cambridge/London | Biologics | Rare diseases | Preclinical | 1 轮 | 2026-03-24 Series A $87M | 87 | Frazier Life SciencesFrazier Life Sciences / F-Prime Capital / Frazier Life Sciences, F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital and Cambridge Enterprise Ventures |
私有 | 自建(M) | ? | — | — | ||
| 230 | Ona Therapeutics | 欧洲 | Spain / Barcelona | — | — | — | 1 轮 | 2026-06-04 Series B $87M | 87 | Columbus Venture PartnersColumbus Venture Partners, Mérieux Equity Partners, COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV and Ysios Capital |
私有 | 混合(M) | 是 | @OnaTherapeutics | 401 | ||
| 231 | Augustine Therapeutics | 欧洲 | Belgium / Leuven | Small molecules | CNS disorders | Preclinical | 1 轮 | 2025-03-24 Series A $85M | 85 | Jeito CapitalNovo Holdings, Jeito Capital / Eli Lilly and Company, Novo Holdings / Jeito Capital, Novo Holdings, Asabys Partners, Eli Lilly, AdBio Partners, V-Bio Ventures, PMV, VIB, Gemma Frisius Fund, Charcot-Marie-Tooth Research Foundation and Newton Biocapital |
私有 | 混合(M) | ? | ✓ | — | — | |
| 232 | Cytospire Therapeutics | 欧洲 | UK / London | — | — | — | 1 轮 | 2026-05-05 Series A $83M | 83 | 4BIO Capital4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth, LifeArc Ventures, Modi Ventures, Medical Incubator Japan and Pathway Bioventures |
私有 | 自建(M) | ? | — | — | ||
| 233 | Charm Therapeutics | 欧洲 | UK / London | Small molecules | Cancer | Preclinical | 1 轮 | 2025-09-02 Series B $80M | 80 | New Enterprise AssociatesNEA, SR One / OrbiMed, F-Prime Capital / New Enterprise Associates, SR One, OrbiMed, F-Prime, Khosla Ventures and NVIDIA |
私有 | 自建(M) | ? | ✓ | — | — | |
| 234 | Mosanna Therapeutics | 欧洲 | Switzerland / Basel | Small molecules | Other | Phase 1 | 1 轮 | 2025-06-09 Series A $80M | 80 | Pivotal bioVenture PartnersPivotal bioVenture Partners, EQT Life Sciences / EQT Life Sciences, Forbion / Pivotal bioVenture Partners, EQT Life Sciences, Forbion, Broadview Ventures, Norwest, Forty51 Ventures, Supermoon Capital and High-Tech Gründerfonds |
私有 | 虚拟(M) | ? | — | — | ||
| 235 | Breye | 欧洲 | Denmark / Copenhagen | Small molecules | Eye diseases | Phase 1 | 1 轮 | 2026-09-29 Series A $77M | 77 | Mission BioCapitalMission BioCapital, Novo Holdings / Novo Holdings / Mission BioCapital, Novo Holdings, Sound Bioventures, Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 236 | Actithera | 欧洲 | Norway / Oslo | Radiopharmaceuticals | Cancer | Preclinical | 1 轮 | 2025-07-09 Series A $76M | 76 | M VenturesM Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital / Sofinnova Partners / M Ventures, Hadean Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures, Innovestor's Life Science Fund, Investinor, Surveyor Capital and Arkin Bio Ventures II |
私有 | 自建(M) | ? | — | — | ||
| 237 | Juvenescence | 欧洲 | UK / London | — | — | — | 1 轮 | 2025-05-21 Series B-1 $76M | 76 | Abu Dhabi’s M42 with “follow-on investmeAbu Dhabi’s M42 with “follow-on investments from existing investors.” |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 238 | Adcendo | 欧洲 | Denmark / Copenhagen | Biologics | Cancer | Phase 1 | 1 轮 | 2026-04-14 Series C $75M | 75 | RA Capital ManagementJeito Capital / RA Capital Management, OrbiMed, Novo Holdings |
私有 | 虚拟(M) | 是 | ✓ | — | — | |
| 239 | Beacon Therapeutics | 欧洲 | UK / London | — | — | — | 1 轮 | 2026-01-08 Series C $75M | 75 | Life Sciences at Goldman Sachs AlternatiLife Sciences at Goldman Sachs Alternatives, the Retinal Degeneration Fund, the venture arm of Foundation Fighting Blindness, Syncona Limited, Forbion, Oxford Science Enterprises and Advent Life Sciences |
私有 | 虚拟(M) | 否 | @BeaconTx_ | 1.9k | ||
| 240 | Maxion Therapeutics | 欧洲 | UK / Cambridge | Biologics | Immune diseases | Preclinical | 1 轮 | 2025-03-17 Series A $72M | 72 | General CatalystGeneral Catalyst / Eli Lilly and Company / Led by General Catalyst, with British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital and BGF |
私有 | 自建(H) | ? | — | — | ||
| 241 | Elevara Medicines | 欧洲 | UK / London | Small molecules | Immune diseases | Phase 1 | 2 轮2025-10-21 Series A $70M2025-10-22 Series A $70M |
2025-10-22 Series A $70M | 70 | ForbionForbion, Sofinnova Partners, Weatherden and Monograph Capital / Forbion, Sofinnova Partners |
私有 | 虚拟(M) | ? | ✓ | — | — | |
| 242 | Leyden Labs | 欧洲 | Netherlands / Leiden | Biologics | Infectious diseases | Phase 1 | 1 轮 | 2025-01-09 未披露轮 $70M | 70 | ClavystBio and Polaris PartnersClavystBio, Polaris Partners / Polaris Partners, GV / Co-led by ClavystBio and Polaris Partners, with Qiming Venture Partners and existing investors |
私有 | 自建(M) | ? | @LeydenLabs | 139 | ||
| 243 | NRG Therapeutics | 欧洲 | UK / Stevenage | — | — | — | 1 轮 | 2025-09-08 Series B $67M | 67 | SV Health Investors’ Dementia DiscoverySV Health Investors’ Dementia Discovery Fund, British Business Bank, M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds, Brandon Capital and Parkinson’s UK |
私有 | 混合(M) | 否 | @NrgTherapeutics | 76 | ||
| 244 | Alesta Therapeutics | 欧洲 | Netherlands / Leiden | — | — | — | 1 轮 | 2025-01-08 Series A $67M | 67 | Frazier Life Sciences and Droia VenturesCo-led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital and SSI Strategy |
被收购 | 虚拟(M) | ? | ✓ | — | — | |
| 245 | Oncomatryx | 欧洲 | Spain / Derio (Basque Country) | — | — | — | 1 轮 | 2026-03-30 Series B $67M | 67 | The Spanish government through Centro paThe Spanish government through Centro para el Desarrollo Tecnologico e Innovacion, Kutxa Fundazioa, the Basque Government, Ekarpen VC, BBK and others |
私有 | 混合(L) | 否 | ✓ | @Oncomatryx | 181 | |
| 246 | Haya Therapeutics | 欧洲 | Switzerland / Lausanne | Nucleic acids | Multiple | Preclinical | 1 轮 | 2025-05-08 Series A $65M | 65 | Sofinnova PartnersSofinnova Partners / Sofinnova Partners, Alexandria Venture Investments, Eli Lilly and Company / Sofinnova Partners, Earlybird Venture Capital, Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see ventures, BERNINA Bioinvest and Schroders Capital |
私有 | 自建(H) | ? | @HAYA_lncRNA | 617 | ||
| 247 | ReproNovo | 欧洲 | Switzerland / Geneva | — | — | — | 1 轮 | 2025-05-21 Series A $65M | 65 | Jeito CapitalJeito Capital, AXA IM Alts, M Ventures, Ysios Capital and ALSA Ventures |
私有 | 虚拟(M) | 否 | ✓ | — | — | |
| 248 | MRM Health | 欧洲 | Belgium / Ghent | — | — | — | 1 轮 | 2025-09-04 Series B $64M | 64 | BiocodexBiocodex, ATHOS, BNP Paribas Fortis Private Equity, SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB |
私有 | 混合(H) | 否 | ✓ | — | — | |
| 249 | Exciva | 欧洲 | Germany / Heidelberg | Small molecules | CNS disorders | Phase 1 | 1 轮 | 2026-01-20 Series B $59M | 59 | GimvEQT Life Sciences, Gimv / EQT Life Sciences / Gimv, EQT Life Sciences, Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners and LBBW |
私有 | 虚拟(H) | ? | — | — | ||
| 250 | Storm Therapeutics | 欧洲 | UK / Cambridge | — | — | — | 1 轮 | 2026-04-16 Series C $56M | 56 | M VenturesM Ventures, Pfizer Ventures, Taiho Ventures, IP Group, the UTokyo Innovation Platform and Fast Track Initiative |
私有 | 混合(H) | ? | @storm_tx | 970 | ||
| 251 | Numab Therapeutics | 欧洲 | Switzerland / Wadenswil | Biologics | Multiple | Phase 1 | 2 轮2025-01-09 Series C $55M2025-01-10 C extension $55M |
2025-01-10 C extension $55M | 55 | Cormorant Asset ManagementCormorant Asset Management, Forbion, HBM Healthcare Investment, Novo Holdings / Forbion, Novo Holdings / Cormorant Asset Management, Forbion Growth Opportunities Fund, HBM Healthcare Investment, Novo Holdings, BVF Partners, Octagon Capital Advisors, RTW Investments, and funds and accounts managed by BlackRock |
私有 | 自建(M) | ? | @Numab_Tx | 140 | ||
| 252 | Avidicure | 欧洲 | Netherlands / Leiden | Biologics | Cancer | Preclinical | 1 轮 | 2025-04-24 Seed $50M | 50 | EQT Life Sciences | 私有 | 自建(M) | ? | — | — | ||
| 253 | Kynexis | 欧洲 | Netherlands / Naarden | Small molecules | CNS disorders | Phase 2 | 1 轮 | 2026-08-19 Series A $47M | 47 | Novartis Venture Fund / Forbion | 私有 | 虚拟(M) | ? | ✓ | — | — | |
| 254 | Mironid | 欧洲 | UK / Glasgow | Small molecules | Other | Preclinical | 1 轮 | 2026-08-05 Series B $46M | 46 | Sofinnova Partners | 私有 | 虚拟(M) | ? | — | — | ||
| 255 | Mestag Therapeutics | 欧洲 | UK / Cambridge | Biologics | Cancer | Preclinical | 1 轮 | 2026-03-17 未披露轮 $40M | 40 | GV, Forbion | 私有 | 自建(H) | ? | @Mestagtx | 142 | ||
| 256 | Aerska | 欧洲 | Ireland / Dublin | Nucleic acids | CNS disorders | Preclinical | 1 轮 | 2026-02-09 Series A $39M | 39 | EQT Life Sciences | 私有 | 混合(M) | ? | — | — | ||
| 257 | Coave Therapeutics | 欧洲 | France / Paris | Cell or gene therapy | CNS disorders | Preclinical | 1 轮 | 2025-01-09 Series A $33M | 33 | Novo Holdings, Bpifrance / Novo Holdings | 私有 | 混合(M) | 否 | — | — | ||
| 258 | T-Therapeutics | 欧洲 | UK / Cambridge | Biologics | Multiple | Preclinical | 1 轮 | 2025-11-13 Series A $32M | 32 | Sofinnova Partners, Sanofi Ventures | 私有 | 自建(M) | ? | — | — | ||
| 259 | Alchemab Therapeutics | 欧洲 | UK / London | Biologics | Other | Preclinical | 1 轮 | 2025-09-09 Series A $32M | 32 | Eli Lilly and Company, RA Capital | 私有 | 自建(H) | ? | ✓ | @alchemabtx | 389 | |
| 260 | Tribune Therapeutics | 欧洲 | Sweden / Stockholm | Biologics | Other | Preclinical | 1 轮 | 2025-03-26 Series A $25M | 25 | LifeArc Ventures / Novo Holdings | 私有 | 自建(L) | ? | — | — | ||
| 261 | DISCO Pharmaceuticals | 欧洲 | Germany / Cologne | Biologics | Cancer | Preclinical | 1 轮 | 2025-12-11 Seed $19M | 19 | Ackerman & van HaarenAckerman & van Haaren, NRW.Bank / Sofinnova Partners |
私有 | 自建(H) | ? | — | — | ||
| 262 | Signadori Bio | 欧洲 | France / Paris | Cell or gene therapy | Cancer | Preclinical | 1 轮 | 2026-05-06 Seed $13M | 13 | Taiho Capital / Sofinnova Partners | 私有 | 虚拟(M) | 否 | — | — |
本页数字与下一篇《自建、混合还是虚拟》一致;逐家证据与来源见该篇第二部分。
本文为个人研究笔记,结论基于成文时可获得的公开信息;带〔估算〕〔推断〕或⚠️的数字未经独立核实。